{
    "version": "https://jsonfeed.org/version/1",
    "title": "BHOLE",
    "description": "",
    "home_page_url": "https://BGASM.github.io/medNotes",
    "feed_url": "https://BGASM.github.io/medNotes/feed.json",
    "user_comment": "",
    "author": {
        "name": "William Slattery"
    },
    "items": [
        {
            "id": "https://BGASM.github.io/medNotes/chemotherapy-ii.html",
            "url": "https://BGASM.github.io/medNotes/chemotherapy-ii.html",
            "title": "Chemotherapy II",
            "summary": "Anti-MetabolitePyrimidine ANtagonist: Cytarabine and GemcitabineToxicityPurine AntagonistTumor AntibioticsAnthracyclinesAnthracycline Mechanism:Antrhacycline CardiotoxicityAntrhacenedionesAntrhacenedione Mechanism:BleomycinBleomycin Mechanism:Bleomycin ToxicityTopoisomerase inhibitorsTopoisomerase I - Campthothecins: Topotecan and IrinotecanMechanism:Topoisomerase II -Podophyllotoxins: Etoposide and TeniposideMechanism:Microtubule InhibitorsTaxanes: Paclitaxel, Docetaxel, nab-PaclitaxelMechanism:Vinca Alkaloids: Vincristine, Vinorelbine, VinblastineMechanism:Adverse Effects:Drug Interactions:Targeted TherapiesTyrosine Kinase Inhibitors and Monoclonal AntibodiesTKIs “nibs” - Imatinib, Dasatinib, NilotinibMonoclonal&hellip;",
            "content_html": "<ul>\n<li><a href=\"#anti-metabolite\">Anti-Metabolite</a><ul>\n<li><a href=\"#pyrimidine-antagonist-cytarabine-and-gemcitabine\">Pyrimidine ANtagonist: Cytarabine and Gemcitabine</a><ul>\n<li><a href=\"#toxicity\">Toxicity</a></li>\n</ul>\n</li>\n<li><a href=\"#purine-antagonist\">Purine Antagonist</a></li>\n</ul>\n</li>\n<li><a href=\"#tumor-antibiotics\">Tumor Antibiotics</a><ul>\n<li><a href=\"#anthracyclines\">Anthracyclines</a><ul>\n<li><a href=\"#anthracycline-mechanism\">Anthracycline Mechanism:</a></li>\n<li><a href=\"#antrhacycline-cardiotoxicity\">Antrhacycline Cardiotoxicity</a></li>\n</ul>\n</li>\n<li><a href=\"#antrhacenediones\">Antrhacenediones</a><ul>\n<li><a href=\"#antrhacenedione-mechanism\">Antrhacenedione Mechanism:</a></li>\n</ul>\n</li>\n<li><a href=\"#bleomycin\">Bleomycin</a><ul>\n<li><a href=\"#bleomycin-mechanism\">Bleomycin Mechanism:</a></li>\n<li><a href=\"#bleomycin-toxicity\">Bleomycin Toxicity</a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li><a href=\"#topoisomerase-inhibitors\">Topoisomerase inhibitors</a><ul>\n<li><a href=\"#topoisomerase-i---campthothecins-topotecan-and-irinotecan\">Topoisomerase I - Campthothecins: Topotecan and Irinotecan</a><ul>\n<li><a href=\"#mechanism\">Mechanism:</a></li>\n</ul>\n</li>\n<li><a href=\"#topoisomerase-ii--podophyllotoxins-etoposide-and-teniposide\">Topoisomerase II -Podophyllotoxins: Etoposide and Teniposide</a><ul>\n<li><a href=\"#mechanism-1\">Mechanism:</a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li><a href=\"#microtubule-inhibitors\">Microtubule Inhibitors</a><ul>\n<li><a href=\"#taxanes-paclitaxel-docetaxel-nab-paclitaxel\">Taxanes: Paclitaxel, Docetaxel, nab-Paclitaxel</a><ul>\n<li><a href=\"#mechanism-2\">Mechanism:</a></li>\n</ul>\n</li>\n<li><a href=\"#vinca-alkaloids-vincristine-vinorelbine-vinblastine\">Vinca Alkaloids: Vincristine, Vinorelbine, Vinblastine</a><ul>\n<li><a href=\"#mechanism-3\">Mechanism:</a></li>\n<li><a href=\"#adverse-effects\">Adverse Effects:</a></li>\n<li><a href=\"#drug-interactions\">Drug Interactions:</a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li><a href=\"#targeted-therapies\">Targeted Therapies</a></li>\n<li><a href=\"#tyrosine-kinase-inhibitors-and-monoclonal-antibodies\">Tyrosine Kinase Inhibitors and Monoclonal Antibodies</a><ul>\n<li><a href=\"#tkis-nibs---imatinib-dasatinib-nilotinib\">TKIs “nibs” - Imatinib, Dasatinib, Nilotinib</a></li>\n<li><a href=\"#monoclonal-antibodies---trastuzumab\">Monoclonal Antibodies - Trastuzumab</a></li>\n</ul>\n</li>\n<li><a href=\"#hormone-receptor-modulators\">Hormone Receptor Modulators</a><ul>\n<li><a href=\"#estrogen-and-breast-cancer\">Estrogen and Breast Cancer</a><ul>\n<li><a href=\"#serm---tamoxifen\">SERM - Tamoxifen</a></li>\n<li><a href=\"#aromatase-inhibitors\">Aromatase Inhibitors</a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li><a href=\"#epigenetic-modifiers\">Epigenetic Modifiers</a><ul>\n<li><a href=\"#hypomethylating-agents-azacitidine-and-decitabine\">Hypomethylating Agents Azacitidine and Decitabine</a></li>\n<li><a href=\"#histone-deacetylase-hdac-inhibitors---vorinostat-romidepsin-belinostat-panobinostat\">Histone Deacetylase (HDAC) inhibitors - Vorinostat, romidepsin, belinostat, panobinostat</a></li>\n</ul>\n</li>\n<li><a href=\"#--mild-myelosuppression\">- Mild myelosuppression</a></li>\n<li><a href=\"#immunomodulatory-drugs\">Immunomodulatory Drugs</a><ul>\n<li><a href=\"#immuno-blockade-therapy\">Immuno Blockade Therapy</a><ul>\n<li><a href=\"#ctla-4\">CTLA-4:</a></li>\n<li><a href=\"#pd1\">PD1</a></li>\n<li><a href=\"#side-effects-of-checkpoint-inhibitors\">Side Effects of checkpoint inhibitors</a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li><a href=\"#miscellaneous\">Miscellaneous</a><ul>\n<li><a href=\"#l-asparaginase\">L-Asparaginase</a></li>\n<li><a href=\"#proteasome-inhibitors---bortezombi-and-carfilzomib\">Proteasome Inhibitors - Bortezombi and Carfilzomib</a></li>\n<li><a href=\"#dofferentiating-agents\">Dofferentiating Agents</a></li>\n<li><a href=\"#chemoprotectant-or-antidotes\">Chemoprotectant or Antidotes</a></li>\n</ul>\n</li>\n</ul>\n<h2 id=\"anti-metabolite\">Anti-Metabolite</h2>\n<p><strong>Anti-metabolites are specific for S phase</strong></p>\n<ul>\n<li>Types:<ol>\n<li>Folate Antagonist - methotrexate</li>\n<li>Pyrimidine Antagonist - 5-FU</li>\n<li>Purine Antagonist - 6-mercaptopurine<h3 id=\"pyrimidine-antagonist-cytarabine-and-gemcitabine\">Pyrimidine ANtagonist: Cytarabine and Gemcitabine</h3>\nIncorporate into cell and bind to DNA<h4 id=\"toxicity\">Toxicity</h4>\nToxic to normal cells that proliferate rapidly<ul>\n<li>GI</li>\n<li>Bone marrow</li>\n</ul>\n</li>\n</ol>\n</li>\n<li>Dose dependent<ul>\n<li>IV bolus dose: incorporate into RNA - more myelosuppression</li>\n<li>IV continuous dose: incorporate into DNA - more skin toxicity <em>hand and foot syndrome</em></li>\n<li>Prolonged administration damages DNA in epithelial cells of the skin.<ul>\n<li>Hand and Foot:</li>\n</ul>\n</li>\n<li>Gradual development of pain, redness, numbness and bilateral desquamation of palms<h3 id=\"purine-antagonist\">Purine Antagonist</h3>\nFake purine bases.<ul>\n<li>6-MP decoy for hypoxanthine</li>\n<li>6-TG decoy for Guanine</li>\n<li><strong>Require intracellular activation. Parent compount can cause toxicity</strong></li>\n<li><strong>Reduce HGPRT enzyme activity</strong></li>\n<li>6-TG is more potent</li>\n<li><strong>6-TG causes more GI toxicity (more myelosuprressive)</strong></li>\n</ul>\n</li>\n<li><strong>Allopurinol</strong> (drug for gout and tumor lysis syndrome) blocks xanthine oxidase and leads to <strong>accumulation of 6-MP</strong><ul>\n<li><strong>Immunosuppressive</strong></li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"tumor-antibiotics\">Tumor Antibiotics</h2>\n<p><strong>Specific for cells in G2 phase</strong></p>\n<ol>\n<li>Anthracyclines: <strong>Doxorubicin, epirubicin</strong>, idarubicin, daunorubicin</li>\n<li>Anthracenediones: Mitoxanthrone</li>\n<li>Bleomycin</li>\n</ol>\n<ul>\n<li><strong>Doxorubicin and epirubicin most active</strong> chemo drugs available<h3 id=\"anthracyclines\">Anthracyclines</h3>\n<h4 id=\"anthracycline-mechanism\">Anthracycline Mechanism:</h4>\n</li>\n</ul>\n<p><strong>Intercalate between base pairs of DNA helix</strong> </p>\n<ul>\n<li><strong>Inhibit topoisomerase II</strong> (<em>g2 phase</em>)</li>\n<li><strong>Supercoiled DNA</strong></li>\n<li><strong>Form free radicals</strong><h4 id=\"antrhacycline-cardiotoxicity\">Antrhacycline Cardiotoxicity</h4>\n</li>\n</ul>\n<p><strong>Cumulative cardiac toxicity</strong></p>\n<ul>\n<li><strong>Formation of ROS</strong></li>\n<li><strong>Damage to Topo II in cardiomyocytes</strong><ul>\n<li>Damage with all doses, but symptoms appear with <strong>cumulative exposure</strong></li>\n<li>Liposome-encapsulated antrhacycline delay cardiotoxicity</li>\n<li><strong>Chemoprotectant Dexrazoxane (DZR)</strong> <em>prevents cardiac injury</em> but <em>inhibits antitumor activity</em> of anthracyclines<h3 id=\"antrhacenediones\">Antrhacenediones</h3>\n<h4 id=\"antrhacenedione-mechanism\">Antrhacenedione Mechanism:</h4>\nSimilar to anthracyclines</li>\n<li><strong>DNA intercalataion and TOPO II inhibition</strong></li>\n<li><strong>Free radical formation</strong> (<em>nitrogen dioxide</em>)</li>\n<li><strong>NOT ROS</strong></li>\n</ul>\n</li>\n<li><strong>Cardiotoxic, but delayed</strong><h3 id=\"bleomycin\">Bleomycin</h3>\n<h4 id=\"bleomycin-mechanism\">Bleomycin Mechanism:</h4>\n<ul>\n<li>Bind to GC-rich portion of DNA and partially <strong>intercalate</strong></li>\n<li><em>Bind divalent metals such as</em> <strong>iron, the active ligand</strong></li>\n<li>Oxygen binds to iron and produce <strong>free radicals</strong></li>\n<li>Free radicals make <strong>single-strand breaks</strong><h4 id=\"bleomycin-toxicity\">Bleomycin Toxicity</h4>\n</li>\n<li><strong>Cumulative toxicity</strong></li>\n<li>Detoxified by hydrolase</li>\n<li>Hydrolase low in <strong>skin and lungs</strong></li>\n</ul>\n</li>\n</ul>\n<h2 id=\"topoisomerase-inhibitors\">Topoisomerase inhibitors</h2>\n<ul>\n<li><strong>Specific for G2/S phase</strong><h3 id=\"topoisomerase-i---campthothecins-topotecan-and-irinotecan\">Topoisomerase I - Campthothecins: Topotecan and Irinotecan</h3>\n<h4 id=\"mechanism\">Mechanism:</h4>\n</li>\n<li>Topo I relaxes supercoiled DNA</li>\n<li>Inhibitors prevent this. Strands break, lead to apoptosis/</li>\n<li><strong>S phase specific</strong></li>\n<li><strong>Irinotecan has unique GI adverse effect</strong>:<ul>\n<li><strong>Early-onset acute diarrhea - Cholinergic syndrome</strong></li>\n<li>Delayed-onset diarrhea - Unknown mech.<h3 id=\"topoisomerase-ii--podophyllotoxins-etoposide-and-teniposide\">Topoisomerase II -Podophyllotoxins: Etoposide and Teniposide</h3>\n<h4 id=\"mechanism-1\">Mechanism:</h4>\n</li>\n</ul>\n</li>\n<li><strong>Pure Enzyme Inhibitors</strong> meaning <em>NO free radical formation or DNA intercalation</em></li>\n<li>Inhibit TOPO II.<ul>\n<li><strong>Halt progression out of S/G2 phase</strong></li>\n</ul>\n</li>\n<li><em>GI toxicities and myelosuppression</em></li>\n</ul>\n<h2 id=\"microtubule-inhibitors\">Microtubule Inhibitors</h2>\n<ul>\n<li><strong>Specific for M phase</strong><h3 id=\"taxanes-paclitaxel-docetaxel-nab-paclitaxel\">Taxanes: Paclitaxel, Docetaxel, nab-Paclitaxel</h3>\n<h4 id=\"mechanism-2\">Mechanism:</h4>\n</li>\n<li><strong>Mitotic spindle poisons</strong></li>\n<li><strong>Stabilize MT’s against depolymerization</strong></li>\n<li><strong>Neurotoxic</strong></li>\n<li><em>Myelosuppressive</em></li>\n</ul>\n<h3 id=\"vinca-alkaloids-vincristine-vinorelbine-vinblastine\">Vinca Alkaloids: Vincristine, Vinorelbine, Vinblastine</h3>\n<h4 id=\"mechanism-3\">Mechanism:</h4>\n<ul>\n<li><strong>Block mitotic cell division in M phase</strong></li>\n<li>Bind to tubulin and <strong>inhibit polymerization MT’s</strong><h4 id=\"adverse-effects\">Adverse Effects:</h4>\n</li>\n<li>MT’s are primary structural element of mitotic spindle in nerve structures</li>\n<li><strong>Neurotoxicity</strong><ul>\n<li><strong>Dose and schedule dependent</strong></li>\n<li>Autonomic and cranial nerve neuropathy</li>\n<li>Encephalopath</li>\n<li><strong>Vinorelbine is least neurotoxic but causes more myelosuppression</strong></li>\n</ul>\n</li>\n<li>GI autonomic dysfunction (<em>bloating, constipation, abd pain</em>) complicates therapy with vinca alkaloids<h4 id=\"drug-interactions\">Drug Interactions:</h4>\n</li>\n<li><strong>Metabolic inhibitors</strong> can lead to <strong>overexposure</strong> to vinca alkaloid<ul>\n<li><em>P450</em><h2 id=\"targeted-therapies\">Targeted Therapies</h2>\nTargeted Therapies attack specific molecular targets.</li>\n</ul>\n</li>\n<li>Very effective if specific target is driving cancer-</li>\n<li>Less toxic that traditional-</li>\n<li>Generally not curative as single agents-\nTraditional vs Targeted:</li>\n<li>Reduce mortality</li>\n<li>Stop disease progression</li>\n<li>More toxic<h2 id=\"tyrosine-kinase-inhibitors-and-monoclonal-antibodies\">Tyrosine Kinase Inhibitors and Monoclonal Antibodies</h2>\n<h3 id=\"tkis-nibs---imatinib-dasatinib-nilotinib\">TKIs “nibs” - Imatinib, Dasatinib, Nilotinib</h3>\n</li>\n<li>Imatinib used for CML. Inhibit proliferation of bcr-abl fusion prot.<ul>\n<li><strong>Binds to ATP binding pocket of Tyr kinase</strong></li>\n</ul>\n</li>\n<li>TKI’s are part of normal cellular pathways</li>\n<li>Inhbition of TKI can cause <strong>off-target</strong> effects:<ul>\n<li>MoA has unintended organ insults</li>\n<li>Myelosuppression<h3 id=\"monoclonal-antibodies---trastuzumab\">Monoclonal Antibodies - Trastuzumab</h3>\n</li>\n</ul>\n</li>\n<li>MAB that targets Her2/neu receptor.\n<strong>- HER2/neu is also expressed in cardiomyocytes</strong> - which explains <strong>off-target cardiotoxicity</strong>  <h2 id=\"hormone-receptor-modulators\">Hormone Receptor Modulators</h2>\n<h3 id=\"estrogen-and-breast-cancer\">Estrogen and Breast Cancer</h3>\nEstrogen fuels growth of breast cancer cells</li>\n<li>Inhibitors:<ul>\n<li>Pre menopause: Selective Estrogen Receptor Modulators <strong>SERMs</strong> - <strong>Tamoxifen</strong></li>\n<li>Post menopause: <strong>Aromatase Inhibitors</strong> - <strong>Exemestane</strong></li>\n<li>Average age of menoupause is 51 yrs.<h4 id=\"serm---tamoxifen\">SERM - Tamoxifen</h4>\n75% of breast cancer epxpress estrogen receptors <em>ER+</em>, 65% express progesterone receptors <em>PR+</em></li>\n</ul>\n</li>\n<li>Tamoxifen for hormonal therapy:<ul>\n<li>Prodrug. <strong>Hydroxymetabolites</strong> provide the anti-tumor activity.</li>\n<li>Partial estrogen agonist</li>\n<li>Antagonist in breast tissue</li>\n<li>Can prevent breast cancer in high risk PT and treat those with advanced or localized disease</li>\n<li><strong>Adverse</strong>: Due to estrogenic effects - Uterine Cancer<h4 id=\"aromatase-inhibitors\">Aromatase Inhibitors</h4>\n<code>Exemestane, Letrozole, Anastrozole – Inhibit the enzyme aromatase ONLY in peripheral tissue (NOT in ovaries) so only useful in post-menopausal women</code><h2 id=\"epigenetic-modifiers\">Epigenetic Modifiers</h2>\n<h3 id=\"hypomethylating-agents-azacitidine-and-decitabine\">Hypomethylating Agents Azacitidine and Decitabine</h3>\n</li>\n</ul>\n</li>\n<li><strong>Inhibit DNA methyltransferases</strong><ul>\n<li>Hypomethylation</li>\n<li>Apoptosis</li>\n<li>Reverse epigenetic silencing</li>\n</ul>\n</li>\n<li>Need to be incorporated into DNA through reduced metabolite<ul>\n<li>One cycle of replication gets hemimethylated. Two cycles for entire demthylation.</li>\n<li><strong>Several doses</strong> are needed for clinical response.<ul>\n<li>At high doses it acts like anti-pyrimidine (<em>cytotoxic and anti-metabolite</em>)<h3 id=\"histone-deacetylase-hdac-inhibitors---vorinostat-romidepsin-belinostat-panobinostat\">Histone Deacetylase (HDAC) inhibitors - Vorinostat, romidepsin, belinostat, panobinostat</h3>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>HDAC catalyzes <strong>removal of acetyl groups</strong> from histones.<ul>\n<li>DNA wraps more tightle when acetyl groups are removed. Silenced, euchromatin.</li>\n<li>This prevents the expression of <strong>tumor suppressor genes</strong></li>\n</ul>\n</li>\n<li>HDAC inhibitors bind to the enzyme and prevent it.</li>\n<li>Increased acetylation of DNA, and <strong>expression of the silenced genes</strong></li>\n<li><strong>Adverse Effects</strong>:<ul>\n<li>Cardiac Toxicity</li>\n<li>GI Tox</li>\n<li>Mild myelosuppression</li>\n</ul>\n</li>\n</ul>\n<hr>\n<h2 id=\"immunomodulatory-drugs\">Immunomodulatory Drugs</h2>\n<h3 id=\"immuno-blockade-therapy\">Immuno Blockade Therapy</h3>\n<pre><code>T cell activation requires two signals: TCR and B7/CD28 co-stim. \nIn normal situations, T cell de-activate themselves by binding their CTLA4 receptor to CD80 on DCs. \nPD1 pathway delivers inhibitory signals to immune system to slow down. Limits initiation and duration of immune response. When a T cell activates it induces PD1 expression.\nProduction if IFNg also upregulates PD1L, which binds to PD1 and turns it off.\nTumor cells evade by either upregulating the PD1L or by upregulating CD80 and binding T cell CTLA4, downregulating them, or by hiding CD28.</code></pre><ul>\n<li>Anti-CTLA4: Ipilimumbab</li>\n<li>Anti-PD1: Pembrolizumab, Nivolumab</li>\n<li>Anti-PD1L: Atezolizumab, Avelumab, Durvalumab<h4 id=\"ctla-4\">CTLA-4:</h4>\n</li>\n<li>Receptors are distributed through secondary lymphoid organs</li>\n<li>Target recently primed T cells</li>\n<li>Phosphatases SHP1,2, PP2a</li>\n<li>Inhibit glycolysis<h4 id=\"pd1\">PD1</h4>\n</li>\n<li>Inflamed peripheral tissue and secondary lymphoid organs</li>\n<li>Target Effector T cells</li>\n<li>Phosphatase SHP2</li>\n<li>Inhibit Glycolysis and induce Fatty Acid Oxidation<h4 id=\"side-effects-of-checkpoint-inhibitors\">Side Effects of checkpoint inhibitors</h4>\n</li>\n<li>They can cause autoimmune side effects<ul>\n<li>MAB’s are highly specific, so not an issue of off-target toxicities</li>\n<li><strong>Substantial on-target toxiciites possible</strong><ul>\n<li>Pembrolizumab therapy caused thyroiditis and thyroid dysfunction</li>\n</ul>\n</li>\n<li>Majority of cases result in irreversible hypothyroidism</li>\n<li>Similar issues of thyroid dysfunction observed in melanoma\n– Other immune related adverse events can occur with systemic administration of immune checkpoint inhibitors </li>\n<li>dermatologic, gastrointestinal, hepatic, endocrine inflammatory events </li>\n<li>temporary immunosuppression with corticosteroids, TNFα antagonists, or other agents effective in most cases but can be fatal</li>\n<li>Dermatitis, Colitis, Hepatitis</li>\n</ul>\n</li>\n<li>Side Effects of CAR T therapy:<ul>\n<li>Cytokine Release Syndrome<ul>\n<li>When the CAR T cell engages surrogate antigens it releases a variety of cytokines that get picked up by macrophages and other innate immune cells.</li>\n<li>They go nuts for it and start shitting the bed too.</li>\n<li>CAR T cells are able to get into CSF, and it is possible that their cytokine release would make the BBB permeable to more CAR T cells and other immune cells.</li>\n</ul>\n</li>\n<li>Neurotoxicity, Hemodynamic instability (tachycardia, hypotension, capillary leak) Organ Dysfunction (AST and ALT elevation, Hyperbilirubinemia, Respiratory Failure)<h2 id=\"miscellaneous\">Miscellaneous</h2>\n<h3 id=\"l-asparaginase\">L-Asparaginase</h3>\n</li>\n</ul>\n</li>\n<li><strong>L-Asparaginase is specific for G1 phase</strong></li>\n<li>All cells require Asparagine</li>\n<li>Normal cells, but <strong>NOT ALL</strong> cells can synthesize their own.</li>\n<li>Hydrolysis of L-aspargine derprives tumor cells of the necessary amino acid.</li>\n<li>Used to treat ALL (<em>Acute Lymphoblastic Leukemia</em>)</li>\n<li><strong>Must be adminstered within 9-10 days before OR 24 hours after treatment with antifolate methotrexate</strong><ul>\n<li>Concurrent asparginase use can block methotrexate (S phase) activity by inhibitin cell replication and inhibiting glutaminatinase <em>which methotrexate requires for optimal accumulation</em><ul>\n<li>Aspariginase before methotrexate is <strong>ANTAGONISTIC</strong></li>\n<li>Methotrexate before asparaginase may be <strong>SYNERGYSTIC</strong><h3 id=\"proteasome-inhibitors---bortezombi-and-carfilzomib\">Proteasome Inhibitors - Bortezombi and Carfilzomib</h3>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Normall cells the proteasome degrades intracellular proteins and maintains homeostasis</li>\n<li><strong>Myeloma</strong> cells can be effectively <strong>killed by proteasome inhibitors</strong></li>\n<li><strong>Bortezomib</strong> binds <strong>reversibly</strong> to proteasome</li>\n<li><strong>Carfilzomib</strong> binds <strong>irreversibly</strong></li>\n<li>Inhibition of proteasome leads to an accumulation of protein in tumor cells that lead to cell death through the unfolded protein pathway.</li>\n<li>Proteasome inhibitors also inhibit NF-KB that is common in cancer cells.</li>\n<li><strong>Adverse Effects</strong>:<ul>\n<li>Peripheral neuropathy (reversible)</li>\n<li>Myelosuppresion</li>\n<li>Mild Gi effects<h3 id=\"dofferentiating-agents\">Dofferentiating Agents</h3>\n</li>\n</ul>\n</li>\n<li>High tumor grades are poorly differentiated</li>\n<li>Alternative to inducing apoptosis</li>\n<li>Limited success EXCEPT: <ul>\n<li>ATRA or ATO for APL</li>\n<li>9-cis RA - regression of premalignant lesions in mouth and throat.<h3 id=\"chemoprotectant-or-antidotes\">Chemoprotectant or Antidotes</h3>\n<ul>\n<li><strong>Amifostine (PRODRUG)</strong> - activated by alkaline phosphatases that are <strong>NOT</strong> on cancer cells.</li>\n<li>Scavenges <strong>free radicals</strong> and prevents <strong>cisplatin-induced nephrotoxicity</strong></li>\n<li><strong>MESNA prevents cyclophosphamide</strong> toxicity <strong>hemorrhagic cystitis</strong> by inactivating <strong>acrolein</strong></li>\n<li><strong>Methylene blue</strong> treats <strong>CNS toxicity</strong> caused by <strong>ifosamide</strong> by inhibiting <strong>chloroacetaldehyde</strong></li>\n<li><strong>Dexrazoxane prevents cardiotoxicity by anthracycline</strong> by <strong>chelating iron</strong> and preventing hyrdoxyl radicals</li>\n<li><strong>Folinic Acid (leocovorin) reduces methotrexate</strong> toxicity <strong>but enhances</strong> effect of pyrimidine antagonist <strong>5-FU</strong> by <em>inhibiting thymidylate synthase</em></li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-12-03T21:20:33-05:00",
            "date_modified": "2020-12-03T21:20:33-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/chemotherapy-i.html",
            "url": "https://BGASM.github.io/medNotes/chemotherapy-i.html",
            "title": "Chemotherapy I",
            "summary": "Chemotherapy IHallmarks of CancerChallengesMultiple mutationsHeterogeneityEpigeneticsTumor MicroenvironmentDrug Resistance:Chemotherapy:History:Types of ChemoTargetting the Cell CycleTherapeutic WindowDrug Resistance: Goldie-Coldman ModelCombination ChemotherapyRoute of Administration - 5-FUPharmacokineticsAlkylating AgentsAlkylating Mustards:General Mechanism:Reactivity:Notes on MustardsAlkylating Mustards: Cyclophosphamide and Ifosfamide are pro-drugsAlkylating Mustards: Cyclophosphamide and Ifosfamide and acrolein toxicityAlkylating Mustards: Ifosfamide Neurotoxicity:Alkylating NitrosoureasAlkylating TriazenesAlkylating Platinum&hellip;",
            "content_html": "<ul>\n<li><a href=\"#chemotherapy-i\">Chemotherapy I</a><ul>\n<li><a href=\"#hallmarks-of-cancer\">Hallmarks of Cancer</a><ul>\n<li><a href=\"#challenges\">Challenges</a></li>\n</ul>\n</li>\n<li><a href=\"#multiple-mutations\">Multiple mutations</a></li>\n<li><a href=\"#heterogeneity\">Heterogeneity</a></li>\n<li><a href=\"#epigenetics\">Epigenetics</a></li>\n<li><a href=\"#tumor-microenvironment\">Tumor Microenvironment</a></li>\n<li><a href=\"#drug-resistance\">Drug Resistance:</a><ul>\n<li><a href=\"#chemotherapy\">Chemotherapy:</a></li>\n</ul>\n</li>\n<li><a href=\"#history\">History:</a></li>\n</ul>\n</li>\n<li><a href=\"#types-of-chemo\">Types of Chemo</a><ul>\n<li><a href=\"#targetting-the-cell-cycle\">Targetting the Cell Cycle</a></li>\n<li><a href=\"#therapeutic-window\">Therapeutic Window</a></li>\n<li><a href=\"#drug-resistance-goldie-coldman-model\">Drug Resistance: Goldie-Coldman Model</a></li>\n<li><a href=\"#combination-chemotherapy\">Combination Chemotherapy</a></li>\n<li><a href=\"#route-of-administration---5-fu\">Route of Administration - 5-FU</a></li>\n<li><a href=\"#pharmacokinetics\">Pharmacokinetics</a></li>\n</ul>\n</li>\n<li><a href=\"#alkylating-agents\">Alkylating Agents</a><ul>\n<li><a href=\"#alkylating-mustards\">Alkylating Mustards:</a><ul>\n<li><a href=\"#general-mechanism\">General Mechanism:</a></li>\n<li><a href=\"#reactivity\">Reactivity:</a></li>\n<li><a href=\"#notes-on-mustards\">Notes on Mustards</a><ul>\n<li><a href=\"#alkylating-mustards-cyclophosphamide-and-ifosfamide-are-pro-drugs\">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> are <strong>pro-drugs</strong></a></li>\n<li><a href=\"#alkylating-mustards-cyclophosphamide-and-ifosfamide-and-acrolein-toxicity\">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> and acrolein toxicity</a></li>\n<li><a href=\"#alkylating-mustards-ifosfamide-neurotoxicity\">Alkylating Mustards: Ifosfamide Neurotoxicity:</a></li>\n</ul>\n</li>\n<li><a href=\"#alkylating-nitrosoureas\">Alkylating Nitrosoureas</a></li>\n<li><a href=\"#alkylating-triazenes\">Alkylating Triazenes</a></li>\n<li><a href=\"#alkylating-platinum-complexes\">Alkylating Platinum Complexes</a></li>\n<li><a href=\"#alkylating-miscellaneous-procarbazine\">Alkylating Miscellaneous: Procarbazine</a></li>\n</ul>\n</li>\n<li><a href=\"#summary-of-alkylating\">Summary of Alkylating:</a></li>\n<li><a href=\"#summary-of-alkylating-agent-toxicity\">Summary of Alkylating Agent Toxicity:</a><h2 id=\"chemotherapy-i\">Chemotherapy I</h2>\n</li>\n</ul>\n</li>\n<li>Oncogene vs Tumor Suppressor | Gain of Function vs Loss of Function</li>\n<li>Treating oncogenes the goal is to suppress<ul>\n<li>e.g. Tyrosine kinase inhibitor</li>\n</ul>\n</li>\n<li>Treating suppressor genes goal is to activate<ul>\n<li>e.g. MAB cetuximab, which activates p53.<h4 id=\"hallmarks-of-cancer\">Hallmarks of Cancer</h4>\n</li>\n</ul>\n</li>\n<li>Sustained proliferation</li>\n<li>Evade growth suppressors</li>\n<li>Enable replicative immortality</li>\n<li>Resist celld eath</li>\n<li>Activate invastion and metastasis</li>\n<li>Induce angiogenesis</li>\n<li>Genome instability and mutation</li>\n<li>Avoid immune destruction</li>\n<li>Deregulate cellular metabolism</li>\n<li>Tumor promoting inflammation</li>\n<li><figure class=\"post__image\"><img loading=\"lazy\" src=\"https://BGASM.github.io/medNotes/media/posts/9/target.JPG\" sizes=\"(max-width: 48em) 100vw, 768px\" srcset=\"https://BGASM.github.io/medNotes/media/posts/9/responsive/target-xs.JPG 300w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/target-sm.JPG 480w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/target-md.JPG 768w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/target-lg.JPG 1024w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/target-xl.JPG 1360w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/target-2xl.JPG 1600w\"  alt=\"Targetting Cancer\" width=\"716\" height=\"528\" /></figure><h3 id=\"challenges\">Challenges</h3>\n<h4 id=\"multiple-mutations\">Multiple mutations</h4>\n<h4 id=\"heterogeneity\">Heterogeneity</h4>\n<ul>\n<li>2/3 of mutation from single biopsy not detected in different regions of the same tumor<h4 id=\"epigenetics\">Epigenetics</h4>\n</li>\n<li>Normal cells acquire gentic and epigenetic alterations</li>\n<li>Trying to treat cancer can exert additional pressure that accerlates its development of resistant</li>\n<li>Epigenetic therapy can reverse these and restore sensitivity to treatment</li>\n<li>Epigenetic targets enzymes - less toxic than chemo.</li>\n<li><strong>Great if use in combination therapy</strong><h4 id=\"tumor-microenvironment\">Tumor Microenvironment</h4>\n</li>\n</ul>\n</li>\n<li>Multiple cell types that support tumor growth<ul>\n<li><strong>Immune cells</strong></li>\n<li><strong>Fibroblasts</strong></li>\n<li><strong>Endothelial cells</strong></li>\n<li><strong>Vasculature</strong></li>\n<li><em>Pancreatic cancer is not majorally cancerous cells, large portion is *</em>fibroblast***</li>\n</ul>\n</li>\n<li>These microenvironment cells are all <strong>targetable</strong><h4 id=\"drug-resistance\">Drug Resistance:</h4>\n<ul>\n<li><strong>P-glycoprotein efflux pumps</strong> extrude chemotherapy drugs</li>\n<li>Drug metabolism</li>\n<li>Drug sequestration</li>\n<li>Alter signal transduction pathways</li>\n<li>Evade or ignore programmed cell death<h3 id=\"chemotherapy\">Chemotherapy:</h3>\n</li>\n<li>Dev 1940-1960 for solid tumors, hematological malignancies</li>\n<li>Integrated with surgery and radiation</li>\n<li>Obstacles: <ul>\n<li>R</li>\n<li>Hurt normal cells   <h4 id=\"history\">History:</h4>\n</li>\n<li>Mechlorethamine</li>\n<li>Anti-metabolites<ul>\n<li>Methotrexate and 5-fu</li>\n</ul>\n</li>\n<li>Vinca Alkaloid</li>\n<li>Cisplatin to inhibit cell division and cure solid tumors</li>\n<li>Cure of Hodgkin’s disease and ALL</li>\n<li>Adjuvant chemotherapy</li>\n<li>Cure of testicular cancer (vinblastine + bleomycin + cisplatin)</li>\n<li>Targeted Therapy:<ul>\n<li>Gleevec - RTK for CML</li>\n<li>Rituximab - NHL<h2 id=\"types-of-chemo\">Types of Chemo</h2>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><strong>Primary Induction</strong><ul>\n<li><strong>advanced and no alternative</strong></li>\n<li>Palliative</li>\n<li><strong>Improve quality of life</strong></li>\n<li>Prolong time to tumor progression (TTP)</li>\n</ul>\n</li>\n<li><strong>Neoaduvnat</strong><pre><code>- localized cancer\n- Not completely effective\n- Used when surgery is not possible</code></pre></li>\n<li><strong>Adjuvant</strong><pre><code>- follow surgery and radiation\n- Reduce incidence of local and systemic recurrence\n- **Improve overall survival** **OS**\n- **Prolong disease free survival** **DFS**</code></pre><h3 id=\"targetting-the-cell-cycle\">Targetting the Cell Cycle</h3>\n</li>\n<li><figure class=\"post__image\"><img loading=\"lazy\" src=\"https://BGASM.github.io/medNotes/media/posts/9/CELLCYCLE.png\" sizes=\"(max-width: 48em) 100vw, 768px\" srcset=\"https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-xs.png 300w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-sm.png 480w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-md.png 768w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-lg.png 1024w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-xl.png 1360w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-2xl.png 1600w\"  alt=\"Cell Cycle\" width=\"1498\" height=\"779\" /></figure></li>\n<li>Cell survival exponentially related to dose</li>\n<li>Slope of curve related to rate of cell proliferation</li>\n<li><strong>Effective</strong> against those cells that <strong>proliferate rapidly</strong></li>\n<li>Cause of Side Effects<ul>\n<li><strong>Bone marrow</strong> stem cells: Immunocompromise</li>\n<li>GI mucosal cells: </li>\n<li>Hair Follicles: Alopecia</li>\n<li>Ovaries testes<h3 id=\"therapeutic-window\">Therapeutic Window</h3>\n</li>\n<li>Goals are to maximize efficacy and limit tocicity</li>\n<li>Usually use maximum tolerated dose<h3 id=\"drug-resistance-goldie-coldman-model\">Drug Resistance: Goldie-Coldman Model</h3>\n<ul>\n<li>Drug resistance probability is dependednt on intrinsic genetic instabillity</li>\n<li>Even the <em>smallest detectable tumor contains at least 1 drug-resistant clone</em>.</li>\n</ul>\n</li>\n<li><strong>Use all effective chemo drugs</strong><h3 id=\"combination-chemotherapy\">Combination Chemotherapy</h3>\n</li>\n</ul>\n</li>\n<li><figure class=\"post__image\"><img loading=\"lazy\" src=\"https://BGASM.github.io/medNotes/media/posts/9/combo.JPG\" sizes=\"(max-width: 48em) 100vw, 768px\" srcset=\"https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-xs.JPG 300w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-sm.JPG 480w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-md.JPG 768w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-lg.JPG 1024w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-xl.JPG 1360w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-2xl.JPG 1600w\"  alt=\"Combo\" width=\"1578\" height=\"906\" /></figure><h3 id=\"route-of-administration---5-fu\">Route of Administration - 5-FU</h3>\n</li>\n<li>IV bolus dose vs IV continuous infusion<ul>\n<li>IV Bolous: Incorporate into cellular RNA and myelosuppression</li>\n<li>IV Continuous: Incorporate into cellular DNA but skin toxicity</li>\n</ul>\n</li>\n<li>Intermittent dose<ul>\n<li>600mg/m2/cycle</li>\n<li>No cardiac or bladder toxicity</li>\n<li>Secondary malignancies can develop</li>\n</ul>\n</li>\n<li>Single high dose<ul>\n<li>Cardiac toxicity</li>\n<li>Hemorrhagic cystitis</li>\n</ul>\n</li>\n<li>Daily Dose<ul>\n<li>Hemorrhagic cystitis</li>\n<li>Secondary Malignancies<h3 id=\"pharmacokinetics\">Pharmacokinetics</h3>\n</li>\n</ul>\n</li>\n<li>Phramocokinetics represents the kinetics of accumulation and disapperance from plasma</li>\n</ul>\n<h2 id=\"alkylating-agents\">Alkylating Agents</h2>\n<ul>\n<li>Classes:<ol>\n<li><strong>Nitrogen mustards</strong></li>\n<li><strong>Nitrosoureas</strong></li>\n<li><strong>Triazenes</strong></li>\n<li><strong>Platinum complexes</strong><h3 id=\"alkylating-mustards\">Alkylating Mustards:</h3>\n<h4 id=\"general-mechanism\">General Mechanism:</h4>\n</li>\n</ol>\n<ul>\n<li>Drug activated into <em>reative intermediates</em> that <strong>form adducts</strong> at N7 position of guanine in DNA</li>\n<li>Loss of the guanine base (<em>depurination</em>) or miscoding of abnormal base pairing</li>\n<li>Strand break or cross-linking of DNA</li>\n<li>Cell death</li>\n<li><figure class=\"post__image\"><img loading=\"lazy\" src=\"https://BGASM.github.io/medNotes/media/posts/9/alkylate.JPG\" sizes=\"(max-width: 48em) 100vw, 768px\" srcset=\"https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-xs.JPG 300w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-sm.JPG 480w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-md.JPG 768w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-lg.JPG 1024w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-xl.JPG 1360w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-2xl.JPG 1600w\"  alt=\"Alkylate\" width=\"876\" height=\"659\" /></figure><pre><code>Alkylating groups on nitrogen mustard act as &quot;warhead&quot;\nN7 on guanine acts as electron donor, forming adduct\nReact with 2nd guanine, leading to depurination</code></pre><h4 id=\"reactivity\">Reactivity:</h4>\n</li>\n</ul>\n</li>\n<li>Reactivity can be reduced by adding aromatic ring to warhead.</li>\n<li>Less reactivity allows for drug to be given orally.<ul>\n<li>Elderly patients with multiple myeloma or CLL<h4 id=\"notes-on-mustards\">Notes on Mustards</h4>\n<h5 id=\"alkylating-mustards-cyclophosphamide-and-ifosfamide-are-pro-drugs\">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> are <strong>pro-drugs</strong></h5>\n</li>\n<li>Share same active cytotoxic ingredient: phophoramide mustard</li>\n<li>Both metabolized to <strong>acrolein</strong> (toxic to bladder - <strong>hemorrhagic cystitis</strong>)<h5 id=\"alkylating-mustards-cyclophosphamide-and-ifosfamide-and-acrolein-toxicity\">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> and acrolein toxicity</h5>\n</li>\n<li>Hemorrhagic cystitis is dose and schedule dependent</li>\n<li>Acreolin react with nucleophiles in uroepithelium:<ul>\n<li>Prevent with adequate hydration or MESNA</li>\n<li>MESNA inactivates acrolein by binding to and preventing reaction with cellular nucleophiles</li>\n<li>MESNA can prevent hemorrhagic cystitis, but not treat it.</li>\n<li>Treatment is hydration with saline</li>\n<li><strong>Blood in urine of PT treated with cyclophosphamide</strong> is an early warning sign of bladder tox.<h5 id=\"alkylating-mustards-ifosfamide-neurotoxicity\">Alkylating Mustards: Ifosfamide Neurotoxicity:</h5>\n</li>\n</ul>\n</li>\n<li>Ifosfamide shares hemorrhagic cystits toxicity with cyclophosphamide - <strong>acrolein</strong></li>\n<li>Also has Unique CNS neurotoxicity: <ul>\n<li>Chloroacetaldehyde distrub mitochondrial respiratory chain</li>\n<li><strong>Methylene blue is the antidote</strong>. Inhibits formation of <strong>chloroacetaldehyde</strong></li>\n<li><figure class=\"post__image\"><img loading=\"lazy\" src=\"https://BGASM.github.io/medNotes/media/posts/9/ifosamide.JPG\" sizes=\"(max-width: 48em) 100vw, 768px\" srcset=\"https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-xs.JPG 300w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-sm.JPG 480w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-md.JPG 768w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-lg.JPG 1024w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-xl.JPG 1360w ,https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-2xl.JPG 1600w\"  alt=\"Ifosamide\" width=\"871\" height=\"657\" /></figure><h4 id=\"alkylating-nitrosoureas\">Alkylating Nitrosoureas</h4>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Liberate organic isocyanates</li>\n<li>React with lysine residues</li>\n<li>Inactivation of protein, esp DNA repair enzyme</li>\n<li><strong>Highly lipophillic</strong> and used to treat brain tumor because <strong>cross BBB</strong><h4 id=\"alkylating-triazenes\">Alkylating Triazenes</h4>\n</li>\n<li><strong>Methylate</strong> DNA at O6 and N7 positions on <strong>Guanine</strong></li>\n<li>Temozolamide is <strong>highly lipophillic</strong></li>\n</ul>\n<h4 id=\"alkylating-platinum-complexes\">Alkylating Platinum Complexes</h4>\n<ul>\n<li>React with DNA to produce inter and intra strand crosslinnks between adjacent guanines, or guanine and adeninge</li>\n<li>Produce <strong>DNA adducts</strong> that inhibit replication and transcription</li>\n<li><strong>Cisplatin, Carboplatin</strong>: <ul>\n<li>Good for <strong>neck cancer</strong>. </li>\n<li>Cistplatin has <strong>High nephrotoxicity</strong></li>\n<li>Carboplatin has <strong>low nephrotoxicity</strong></li>\n</ul>\n</li>\n<li>Oxaliplatin: <ul>\n<li>More effective for <strong>colon and pancreatic</strong></li>\n</ul>\n<strong>- Nephrotoxicity</strong></li>\n<li>Oxaliplatin more potent than cisplatin in vitro and requires fewer DNA adducts to achieve cytotoxicity</li>\n<li>Carboplatin is a larger molecule than cisplatin; longer retention and different toxicities (less)</li>\n<li><strong>Cytotoxic activity against different tumors and toxicity NOT the same with different platinum compounds</strong><h4 id=\"alkylating-miscellaneous-procarbazine\">Alkylating Miscellaneous: Procarbazine</h4>\n</li>\n<li>MAOI: MAO - Inhibitor<h3 id=\"summary-of-alkylating\">Summary of Alkylating:</h3>\n</li>\n<li>Share similar mechanism of action:<ul>\n<li>Activated to reactive</li>\n<li>Form adducts with cellular macromolecules</li>\n<li>Methylkate DNA\ngernate isocyanates</li>\n<li>Same adverse effects:</li>\n<li>Hemorrhagic cystitis</li>\n<li>CNS toxicity</li>\n<li>Nephrotoxicity and neuropathy</li>\n</ul>\n</li>\n<li>Lipophillic agents have unique applications<h3 id=\"summary-of-alkylating-agent-toxicity\">Summary of Alkylating Agent Toxicity:</h3>\n<ul>\n<li>More toxic to normal, rapidly proliferating cells</li>\n<li>Non-cell cycle specific</li>\n<li>Damage DNA</li>\n<li>Increase mutations</li>\n<li>Secondary malignancies are long-term<ul>\n<li>Leukemias</li>\n<li>Myelodysplastic syndrome</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-12-03T21:18:14-05:00",
            "date_modified": "2020-12-03T21:18:14-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/infarction-shock-and-dic.html",
            "url": "https://BGASM.github.io/medNotes/infarction-shock-and-dic.html",
            "title": "Infarction Shock and DIC",
            "summary": "InfarctionShockCauses:Categories:Stages:Septic ShockDisseminated Intravascular CoagulationConsequences of DICInfarctionInfarction is the process of ischemic necrosis due to either occlusion of arterial supply or of venous drainage.Mainly due to interruption of arterial supply, even if caused by a venous event.Thrombotic events: eg DVT travels to lungs and then occludes&hellip;",
            "content_html": "<ul>\n<li><a href=\"#infarction\">Infarction</a></li>\n<li><a href=\"#shock\">Shock</a><ul>\n<li><a href=\"#causes\">Causes:</a></li>\n<li><a href=\"#categories\">Categories:</a></li>\n<li><a href=\"#stages\">Stages:</a></li>\n</ul>\n</li>\n<li><a href=\"#septic-shock\">Septic Shock</a></li>\n<li><a href=\"#disseminated-intravascular-coagulation\">Disseminated Intravascular Coagulation</a><ul>\n<li><a href=\"#consequences-of-dic\">Consequences of DIC</a><h1 id=\"infarction\">Infarction</h1>\n</li>\n</ul>\n</li>\n<li>Infarction is the process of ischemic necrosis due to either occlusion of arterial supply or of venous drainage.</li>\n<li>Mainly due to interruption of arterial supply, even if caused by a venous event.<ul>\n<li>Thrombotic events: <em>eg</em> DVT travels to lungs and then occludes <strong>arterial</strong> pulmonary artery.</li>\n<li>Vasospasm</li>\n<li>Extrinsic compression by tumor, edema, entrapment in hernia</li>\n<li>Twisting/Torsion</li>\n<li>Vessel rupture</li>\n<li>Venous thrmobosis in organs with single venous outflow.<h2 id=\"infarct-outcome\">Infarct Outcome</h2>\n<ul>\n<li>Dual blood supply (lung, liver, extremities)</li>\n<li>Rate of occlusion: slower occlusion time allow for collateral circulation</li>\n<li>Tissue’s vulnerability to hypoxis<ul>\n<li>Neurons: 3-4 minutes</li>\n<li>Myocardial: 20-30</li>\n<li>Fibroblasts: hours<h2 id=\"gross-morphology\">Gross Morphology</h2>\n</li>\n</ul>\n</li>\n<li>Wedge shaped</li>\n<li>Occluded vessel at apex, organ at base</li>\n<li>Acute poorly defined and slightly hemorrhagic</li>\n<li>Chronic defined with a <em>narrow rim of congestion</em> due to the inflammatory response</li>\n<li>Red vs. White</li>\n<li>Septic vs. Bland<h3 id=\"red-infarct\">Red Infarct</h3>\n<ul>\n<li>RBC-rich blood present</li>\n<li>Venous occlusion</li>\n<li>Loose tissue (lung)</li>\n<li>Dual blood supply</li>\n<li>Congested</li>\n<li>Previous occluison or necrosis.<h3 id=\"white-infarct\">White Infarct</h3>\n</li>\n<li>Organs with end-arterial supply (<em>heart, spleen, kidney</em>)</li>\n<li>Anemic</li>\n<li>Due to lack of nutrients into necrotic zone.<h3 id=\"septic\">Septic</h3>\n</li>\n<li>Occur when infected heart valve vegetation embolize</li>\n<li>Occur when microbes seed an area of necrosis<h2 id=\"microscopic-morphology\">Microscopic Morphology</h2>\n</li>\n</ul>\n</li>\n<li>characterized by ischemic coagulative necrosis<ul>\n<li>Timeline:<ul>\n<li>No visible histologic changes are the norm if ischemia occurs within minutes to a fewhours before death</li>\n<li>4-12 hours, tissue necrosis begins to appear, and acute inflammation begins to show up around the edges</li>\n<li>1-2 days, tissue necrosis is established, and the peripheral inflammatory response is well-defined</li>\n<li>Reparative process follows over the next several days to weeks, where necrotic tissue is removed, and scar tissue replaces<h1 id=\"shock\">Shock</h1>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Systemic hypoperfusion due to reduced cardiac output or blood volume<h2 id=\"causes\">Causes:</h2>\n<ul>\n<li>Severe hemorrhage</li>\n<li>Extensive trauma</li>\n<li>Large myocardial infarction</li>\n<li>Massive PE</li>\n<li>Septicemia<h2 id=\"categories\">Categories:</h2>\n<ol>\n<li>Cardiogenic shock:<ul>\n<li>outflow obstruction (PE)</li>\n<li>myocardial pump failure (myocardial infection, arrhythmia, or pericardial tamponade)</li>\n</ul>\n</li>\n<li>Hypovolemic shock:<ul>\n<li>extensive hemorrhage and/or fluid loss (burns, trauma, vomiting, diarrhea)</li>\n</ul>\n</li>\n<li>Septic shock: <ul>\n<li>vasodilation and peripheral blood pooling caused by overwhelming microbial infection and associated immune response</li>\n</ul>\n</li>\n<li>Neurogenic shock:<ul>\n<li>rarer cause with loss of vascular tone and peripheral pooling (anesthetic accident, spinal cord injury)</li>\n</ul>\n</li>\n<li>Anaphylactic shock: <ul>\n<li>rarer cause with systemic vasodilation and increased vascular permeability (IgE-mediated hypersensitivity)<h2 id=\"stages\">Stages:</h2>\n</li>\n</ul>\n</li>\n</ol>\n<ul>\n<li>Non-progressive:<ul>\n<li>Reflex neurohumoral compensatory mechanisms are activated (catecholamines, ADH, renin-angiotensin axis, etc.) </li>\n<li>Produces tachycardia, peripheral vasoconstriction, and renal conservation of fluid. </li>\n<li>Perfusion of vital organsmaintained.</li>\n</ul>\n</li>\n<li>Progressive:<ul>\n<li>Occurs when persistent hypoxemia leads to anaerobic glycolysis, lactic acid generation, and decreased tissue pH</li>\n<li>This reduces vasomotor response</li>\n<li>Leads to vasodilation, peripheral pooling, decreased CO, ultimately tissue hypoxia</li>\n</ul>\n</li>\n<li>Irreversible:<ul>\n<li>When re-perfusion will not correct death spiral</li>\n<li>Ischemic bowel may lead to superimposed bactermia/septic shock</li>\n<li>Renal failure and tubular necrosis can lead to anuria<h2 id=\"morphology\">Morphology:</h2>\n<h3 id=\"lungs\">Lungs:</h3>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Diffuse alveolar damage<ul>\n<li>Sepsis or trauma</li>\n</ul>\n</li>\n<li>Hyaline membranes lining alveolar spaces</li>\n<li>Interstitial inflammation<h3 id=\"kidneys\">Kidneys:</h3>\n</li>\n<li>Acute tubular necrosis causes oliguira, anuria, electrolyte disturbances</li>\n<li>Swollen vacuolated tubular cells with necrosis and tubular casts<h3 id=\"brain\">Brain:</h3>\n</li>\n<li>Red neurons and neuronal loss<h3 id=\"adrenals\">Adrenals:</h3>\n</li>\n<li>Coritcal cell lipid depletion<h3 id=\"gi\">GI:</h3>\n</li>\n<li>Ischemia with mucosal breakdown<h3 id=\"skin\">Skin:</h3>\n</li>\n<li>Petechial hemorrhage<h2 id=\"clinical-consequences\">Clinical Consequences:</h2>\n</li>\n<li>Cardiogenic and hypovolemic:<ul>\n<li>Hypotension, weak rapid pulse, tachypnea, cool cyanotic skin.</li>\n</ul>\n</li>\n<li>Septic Shock:<ul>\n<li>Skin warm and flushed</li>\n</ul>\n</li>\n<li>Most healthy PT survive hypovolemic shock</li>\n<li>Cardiogenic and spetic are less survivable<h1 id=\"septic-shock\">Septic Shock</h1>\n</li>\n</ul>\n</li>\n<li>Most common in infection by G+/- bacteria and fungi</li>\n<li>Several factors in causation:<ul>\n<li>Inflammatory and counter-inflammatory response</li>\n<li>Endothelia cell activation/injury leading to increased thrombotic, vasodilation, permeability and edema</li>\n<li>DIC</li>\n<li>Metabolic abnormalities<ul>\n<li>Adrenal gland necrosis due to DIC is named Waterhouse-Friderichson Syndrome</li>\n</ul>\n</li>\n<li>Organ dysfunction when systemic hypotension, interstitial edema, small vessel thrombosis all decrease oxygen to organs.<ul>\n<li>Decreased cardiac contractility can lead to cardiovascular collapse</li>\n<li>Increased vascular permeability and endothelial injury lead to lung failure</li>\n<li>Anuria can develop due to acute tubular necrosis or renal failure</li>\n<li>Multiorgan failure: liver, adrenals, etc.<h1 id=\"disseminated-intravascular-coagulation\">Disseminated Intravascular Coagulation</h1>\n</li>\n</ul>\n</li>\n<li>Acute, Subacute, or chronic thrombohemorrhagic disorder.</li>\n<li>Excessive activation of coagulation and thrombi formation.</li>\n<li>Not a primary disease. A secondary response to disease.<h2 id=\"triggers-for-dic\">Triggers for DIC</h2>\n<ul>\n<li>Bacterial endotoxins can inhibit endothelial thrombomodulin production.<ul>\n<li>Endotoxins can also activate factor XII</li>\n</ul>\n</li>\n<li>Antigen-Ab complexes can activate classical complement pathway - which leads to complement fragments that activate platelets and granulocytes</li>\n<li>Massive trauma causes tissue factor release</li>\n<li>Placenta procoagulant proteins can enter circulation</li>\n<li>Hypoxia, acidosis, shock</li>\n<li>Leukemia and adenocarcinomas</li>\n</ul>\n</li>\n<li><strong>Activation of the coagulation cascade and excess thrombin will lead to microthrombi (fibrin thrombi) in tiny vessels throughout the body</strong><ul>\n<li>Fibrin thrombia create ischemia in organs and tissue.</li>\n<li>Compensation for excess fibrin thrombi: ↑↑↑ coagulation inhibitors and fibrinolytic proteins</li>\n<li>Simultaneous consumption of both <strong>procoagulant</strong> and <strong>anticoagulant</strong> proteins exhausts the body’s ability to create more</li>\n<li><strong>End stage: bleeding</strong><h2 id=\"consequences-of-dic\">Consequences of DIC</h2>\n</li>\n<li>Widespread deposition of fibrin</li>\n<li>Ischemia</li>\n<li>Microangipathic hemolytic anemia (<em>RBC fragment trying to squeeze through narrow vasculature</em>)</li>\n<li>Hemorrhagic diathesis as clotting factors and platelets are consumed</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n",
            "image": "https://BGASM.github.io/medNotes/media/posts/8/Myelolipoma_histology_HE.jpg",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-12-03T01:34:30-05:00",
            "date_modified": "2020-12-03T01:34:30-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/adrenergic-inhibitors.html",
            "url": "https://BGASM.github.io/medNotes/adrenergic-inhibitors.html",
            "title": "Adrenergic Inhibitors",
            "summary": "Effects of stimulating Alpha receptors:Effect of inhibiting Alpha receptors:Beta BlockersSelective B1: cardio-selevtiveNon-Selective: B1 and B2Direct effect of Beta Blockers on the Heart: Decreased Heart RateAdverse:Selection:Indirect:Reserpine: cause depletion of catecholamine storesA-methyldopa: false neurotransmitterA-methyltyrosine: catecholamine inhibitorEffects of stimulating Alpha receptors:A1:Contract vascular smooth musclesIncrease foce of heart contractionDilate&hellip;",
            "content_html": "<ul>\n<li><a href=\"#effects-of-stimulating-alpha-receptors\"><strong>Effects of stimulating Alpha receptors:</strong></a></li>\n<li><a href=\"#effect-of-inhibiting-alpha-receptors\"><strong>Effect of inhibiting Alpha receptors:</strong></a></li>\n<li><a href=\"#beta-blockers\">Beta Blockers</a><ul>\n<li><a href=\"#selective-b1-cardio-selevtive\">Selective B1: <em>cardio-selevtive</em></a></li>\n<li><a href=\"#non-selective-b1-and-b2\">Non-Selective: B1 and B2</a></li>\n</ul>\n</li>\n<li><a href=\"#direct-effect-of-beta-blockers-on-the-heart-decreased-heart-rate\"><strong>Direct effect of Beta Blockers on the Heart: Decreased Heart Rate</strong></a><ul>\n<li><a href=\"#adverse\"><strong>Adverse:</strong></a></li>\n<li><a href=\"#selection\"><strong>Selection:</strong></a></li>\n</ul>\n</li>\n<li><a href=\"#indirect\">Indirect:</a><ul>\n<li><a href=\"#reserpine-cause-depletion-of-catecholamine-stores\">Reserpine: cause depletion of catecholamine stores</a></li>\n<li><a href=\"#a-methyldopa-false-neurotransmitter\">A-methyldopa: false neurotransmitter</a></li>\n<li><a href=\"#a-methyltyrosine-catecholamine-inhibitor\">A-methyltyrosine: catecholamine inhibitor</a><h2 id=\"effects-of-stimulating-alpha-receptors\"><strong>Effects of stimulating Alpha receptors:</strong></h2>\n</li>\n</ul>\n</li>\n<li>A1:<ul>\n<li>Contract vascular smooth muscles</li>\n<li>Increase foce of heart contraction</li>\n<li>Dilate Pupils</li>\n<li>Contract prostate</li>\n</ul>\n</li>\n<li>A2:<ul>\n<li>Decrease NE release</li>\n<li>Decrease NE release from CNS</li>\n<li>Decrease Insulin Release<h2 id=\"effect-of-inhibiting-alpha-receptors\"><strong>Effect of inhibiting Alpha receptors:</strong></h2>\n</li>\n</ul>\n</li>\n<li>A1:<ul>\n<li>Vascular relexation</li>\n<li>Decrease force of heart contraction</li>\n<li>Pupil constriction</li>\n<li>Prostate relax</li>\n</ul>\n</li>\n<li>A2:<ul>\n<li>Increase NE</li>\n</ul>\n</li>\n</ul>\n<p>So, when we apply a non-selective Alpha antagonist we get a decrease in TPR (<em>due to the vascular relaxation and the decrease in heart contraction force</em>. ) This decreases blood pressure. Decrease in BP triggers a reflec tachycardia, which is an increase in cardiac output. NE gets released by the A2 inhibition. This NE that is release can then stimulate B1 receptors, which increase heart rate!</p>\n<p>TI: </p>\n<ul>\n<li>Emergency hypertensive crisis</li>\n<li>Preoperative of <strong>pheochromocytoma</strong> == <strong>phentolamine</strong>\n<strong>NOTE: Main use for non-selective alpha is to rapidly decrease blood pressure</strong></li>\n</ul>\n<ol>\n<li><p>Phenoxybenzamine (PBZ): Irreversible and Long Acting. Non-competitive.</p>\n</li>\n<li><h2 id=\"phentolamine-reversible-short-acting\">Phentolamine: Reversible, short acting.</h2>\n<p>Selective A1 antagonists: <strong>LOWER BLOOD PRESSURE</strong></p>\n<ol>\n<li>Prazosin: <strong>HYPERTENSION</strong></li>\n<li>Doxazosin &amp; Terazosin: <strong>HYPERTENSION and BPH</strong></li>\n<li>Tamsulosin: <strong>BPH - Treat lower urinary tract symptoms caused by BPH</strong></li>\n</ol>\n<ul>\n<li>Adverse: <strong>POSTURAL HYPOTENSION AND SYNCOPE 1st dose falls</strong></li>\n<li><strong>Do not cause reflex tachycardia.</strong><h2 id=\"beta-blockers\">Beta Blockers</h2>\n</li>\n</ul>\n<p><strong>All Beta antagonists are competitive</strong></p>\n<ul>\n<li>Well absorved after oral</li>\n<li>Most do not cross BBB</li>\n<li>No absolute selectivity</li>\n</ul>\n<h3 id=\"selective-b1-cardio-selevtive\">Selective B1: <em>cardio-selevtive</em></h3>\n<p>New-AMEBBA:</p>\n<ul>\n<li><strong>N</strong>ebivolol - NO mediated vasodilation</li>\n<li><strong>A</strong>cebutolol - ISA (partial agonist) </li>\n<li><strong>M</strong>etoprolol ←</li>\n<li><strong>E</strong>smolol - Very short duration, used for cardio emergency</li>\n<li><strong>B</strong>etaxolol</li>\n<li><strong>B</strong>isoprolol </li>\n<li><strong>A</strong>tenolol ←<h3 id=\"non-selective-b1-and-b2\">Non-Selective: B1 and B2</h3>\n</li>\n<li>Propranolol ← - Anxiety and Migraines</li>\n<li>Timolol ← Open angle glaucoma (IOP)</li>\n<li>Pindolol - ISA (partial agonist) some B2 activation</li>\n<li>Carvedilol ← A1 receptor antagonist as well. Antioxidant. Blocks Ca2+ Used for heart failure</li>\n<li>Labetalol - ISA (partial agonist) some B2 activation</li>\n<li>Sotalol: Only beta blocker used for only one disease, which is a certain type of arrythmia. <strong>Not even used for hypertenstion.</strong><h3 id=\"direct-effect-of-beta-blockers-on-the-heart-decreased-heart-rate\"><strong>Direct effect of Beta Blockers on the Heart: Decreased Heart Rate</strong></h3>\n<ul>\n<li>Production of Nitric Oxide (<em>potent vasodilator</em>): Nebivolol</li>\n<li>ISA: Intrinsic Sympathomimetic  Activity: Partial B2 activation</li>\n<li>Pindolol, Lavetalol (non-sel with ISA)</li>\n<li>Decrease release of NE from nerve terminals (indirect effect)<pre><code>In some receptors, the B2 receptors that get stimulated by the beta-blocker&#39;s ISA happen to be really close to some A2 receptors. So when the B2 receptors get stimulated, they cause a little NE to get released and then that NE stimulates the nearby A2 receptors, which then has the overall, indirect, effect of decreasing further NE release.</code></pre></li>\n<li>Non-Selective B-blocker (without ISA <em>which means they do not have a partial agonist</em>)</li>\n<li>Direct antagonism of B receptor, there is a decreased release of NE.</li>\n</ul>\n</li>\n<li>Carvedilol blocks Ca entry into the cell, which prevents contraction.</li>\n<li>Antioxidant properties, which produces Nitric Oxide - which is a vasodilator.<ul>\n<li>Decrease Renin.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"adverse\"><strong>Adverse:</strong></h3>\n<ul>\n<li>Bradycardia</li>\n<li>Depressed myocardial contractility and excitability</li>\n<li>Hypoglycemia in diabetic patients<ul>\n<li><strong>Avoid using non-selective B-blocker because they inhibit insulin, glycogenolysis, and gluconeogenesis</strong></li>\n<li><strong>Selective B1 blockers can be fine</strong></li>\n<li>Keep in mind, the selective B1 do not cause tachycardia, instead it promotes bradycardia.</li>\n<li>This is a a note because diabetic patients often notice tachycardia as a sign to get medical assistance.</li>\n</ul>\n</li>\n<li>Sudden withdrawl of </li>\n<li>Propanolol, Carvedilol, Metoprolol can all cross BBB and can have depressive effect on CNS.</li>\n<li>Alter plasma lipids (↑TGL ↓HDL)</li>\n<li>Hepatotoxicity caused by Labetalol</li>\n<li><strong>If patient has asthma</strong> avoid non-selective (ISA) Beta Blockers.<strong>Carvedilol mainly</strong> <em>because it is non-selective for B1 or B2 AND because it has ISA activity.</em></li>\n<li><strong>B2 antagonists cause bronchoconstriction.</strong><h3 id=\"selection\"><strong>Selection:</strong></h3>\n</li>\n<li><strong>PT with bronchospasm or diabetes</strong><ul>\n<li>Selective B1 antag: Metoprolol, Atenolol</li>\n</ul>\n</li>\n<li><strong>PT with bradycardia</strong><ul>\n<li>Use B-blocker with ISA: Pinolol, Acebutolol</li>\n</ul>\n</li>\n<li><strong>PT with hypertension or chronic heart failure</strong><ul>\n<li>Use B-blocker with A1 antag properties: Pindolol, Carvedilol, Acebutolol</li>\n</ul>\n</li>\n</ul>\n</li>\n</ol>\n<h2 id=\"indirect\">Indirect:</h2>\n<h3 id=\"reserpine-cause-depletion-of-catecholamine-stores\">Reserpine: cause depletion of catecholamine stores</h3>\n<ul>\n<li>Inhibits VMAT. Prevents NE vesicular storage.</li>\n<li>As NE gets used up it does not get replaced.</li>\n<li>No catecholamines build up</li>\n<li>Rarely used to treat refractory hypertension</li>\n<li>Causes headaches</li>\n</ul>\n<h3 id=\"a-methyldopa-false-neurotransmitter\">A-methyldopa: false neurotransmitter</h3>\n<ul>\n<li>Gets metabolized as a false-precusor of NE.<ul>\n<li>MethyINE</li>\n<li>Takes up space and not recognized as an NT.</li>\n</ul>\n</li>\n<li>Used for hypertension mainly in pregnancy.</li>\n<li>A2 agonist and false neurotransmitter.</li>\n</ul>\n<h3 id=\"a-methyltyrosine-catecholamine-inhibitor\">A-methyltyrosine: catecholamine inhibitor</h3>\n<ul>\n<li>Inhibits TH tyrosine hydroxylase</li>\n<li>Used in treatment of inoperable pheochromocytoma</li>\n</ul>\n",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-12-02T23:14:44-05:00",
            "date_modified": "2020-12-02T23:14:44-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/hemorrhage-thrombosis-and-embolism-2.html",
            "url": "https://BGASM.github.io/medNotes/hemorrhage-thrombosis-and-embolism-2.html",
            "title": "Hemorrhage Thrombosis and Embolism",
            "summary": "Hemorrhage:Thrombosis:Morphology of thrombusFate of the thrombusEmbolismHemorrhage:Defined as the extravastation of intravascular blood to the extravascular space.Petechiae1-2mm hemorrhage of skin, mucous membrane, or serosal surfaceLocally increased intravasc pressureSeen with low platelet count or defective platelet.Purpura`&gt;=3mm hemorrhage in same location and etiologie of petechiaeMore common in vasculitic&hellip;",
            "content_html": "<ul>\n<li><a href=\"#hemorrhage\">Hemorrhage:</a></li>\n<li><a href=\"#thrombosis\">Thrombosis:</a></li>\n<li><a href=\"#morphology-of-thrombus\">Morphology of thrombus</a></li>\n<li><a href=\"#fate-of-the-thrombus\">Fate of the thrombus</a></li>\n<li><a href=\"#embolism\">Embolism</a></li>\n</ul>\n<h2 id=\"hemorrhage\">Hemorrhage:</h2>\n<ul>\n<li>Defined as the <strong>extravastation of intravascular blood to the extravascular space</strong>.</li>\n<li>Petechiae<ul>\n<li>1-2mm hemorrhage of skin, mucous membrane, or serosal surface</li>\n<li>Locally increased intravasc pressure</li>\n<li>Seen with low platelet count or defective platelet.</li>\n</ul>\n</li>\n<li>Purpura<ul>\n<li>`&gt;=3mm hemorrhage in same location and etiologie of petechiae</li>\n<li>More common in vasculitic state</li>\n<li>Feel the bumps…</li>\n</ul>\n</li>\n<li>Ecchymose<ul>\n<li>Larger &gt;= 1 cm subcutaneous collections of blood bruises.</li>\n<li>RBC undergoing continous breakdown by macrophage.</li>\n</ul>\n</li>\n<li>Hematoma<ul>\n<li>Term used for a collection of hemorrhage that has a well-defined and 3D shape.</li>\n<li>You can use similar terms to describe as we used for edema.</li>\n</ul>\n</li>\n<li>Rapid loss of 20% may be tolerated in healthy adults. <ul>\n<li>Larger losses in a more rapid progression can result in hypovolemic shock.</li>\n</ul>\n</li>\n<li>Recurrent hemorrhage that exits the body can lead to net iron loss and iron deficiency  anemia. <ul>\n<li>The iron in the hemorrhage into a cavity or tissue is typically recovered and recycled.<h2 id=\"thrombosis\">Thrombosis:</h2>\n</li>\n<li>Thrombosis is pathologic<ul>\n<li>An unwanted thrombus.</li>\n</ul>\n</li>\n<li>Thrombus is physiologic and normal<ul>\n<li>Body makes one to initiate a coagulation cascade.<pre><code>What is the point of this clarification?\nWell, a hematoma is a 3d collection of blood within tissue.\nA thrombosis is when an unwanted coagulation cascade has been initiated.\nWe clarify because once again, we need to determine if the red chunk we see within the tissue is due to a **bleeding or coagulation state**. Is it blood, or is it a thrombi?</code></pre>The pathophysiology of hemostatic mechanisms can be determined by looking for sources of abnormalities. - <em>Virchow’s Triad</em>.  </li>\n</ul>\n</li>\n<li>Endothelial Injury/Dysfunction<ul>\n<li>Injury here leads to exposure of ECM, released tissue factor,adherence of plateleys and begins the coagulation cascade.<ol>\n<li>Myocardial infarction</li>\n<li>Atherosclerotic plaques</li>\n<li>Trauma</li>\n</ol>\n</li>\n<li>Dysfunction is any state where normal procoagulant and anticoagulant properties get messed up.<ol>\n<li>Production of more procoagulant factor (plateley adhesion molecule, tissue factor, plasminogen activator inhibitor)</li>\n<li>LESS production of anti-coagulant factors (thrombomodulin, PGI2, tPA)</li>\n</ol>\n</li>\n</ul>\n</li>\n<li>Hypercoagulability <em>thromophilia</em><ul>\n<li>This can be the major etiology for any patient in a clinical setting, loosely defined as any alteration of the coagulation pathway that predisposes one to thrombosis. </li>\n<li>Causes can be genetic (<em>primary</em>) or acquired (<em>secondary</em>) in nature. </li>\n<li><strong>Primary:</strong><ul>\n<li>Factor V Leiden - Factor V </li>\n<li>Prothrombin gene mutation</li>\n<li>Hyperhomocysteinemia</li>\n</ul>\n</li>\n<li><strong>Secondary:</strong><ul>\n<li>Heparin-induced thrombocytopenia syndrome</li>\n<li>Antiphospholipid antibody syndrom</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Abnormal blood flow<ul>\n<li>Disruption of laminar flow allows for coagulation components to start sticking.<ul>\n<li>This can be caused by hyperviscosity, sickle cell anemia, or aneurysms.<h2 id=\"morphology-of-thrombus\">Morphology of thrombus</h2>\nDesribe a thrumbus.</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Arterial Thrombi</li>\n<li>Venous Thrombi<ul>\n<li>DVT</li>\n</ul>\n</li>\n<li>Mural Thrombi</li>\n<li>Vegetations</li>\n<li>Post-mortem<h2 id=\"fate-of-the-thrombus\">Fate of the thrombus</h2>\n</li>\n<li>If the initial insult is not fatal, one of four pathways can be discerned.<ol>\n<li>Propagation – accentuation and prolongation of the hemostatic process</li>\n<li>Embolization – thrombi that disassociate from their main mass and travel to other sites  in the vascular tree.</li>\n<li>Dissolution – Small and/or recent thrombi can undergo fibrinolysis and completely  resolve. <ul>\n<li>Larger and/or older thrombi are more resistant to lysis.</li>\n</ul>\n</li>\n<li>Organization – the process of incorporating a thrombus into the “new normal.” <ul>\n<li>Variable ingrowth of endothelial cells, smooth muscle cells, and fibroblasts to create remodeled vascular channels (<strong>recanalization</strong>), albeit imperfectly.</li>\n</ul>\n</li>\n</ol>\n</li>\n</ul>\n<h2 id=\"embolism\">Embolism</h2>\n<p>An embolism is a <strong>detached intravascular solid, liquid, or gaseous mass</strong> that gets carried by blood to some other site. A <em>thromboembolism</em> is an emolism that originates from a dislodged thrombus. Emboli can lodge in a vessels that are too small to permit passage, and this can cause vascular occlusion, which can lead to ischemic necrosis/infarction.</p>\n<ul>\n<li>Pulmonary Embolus <strong>PE</strong><ul>\n<li>Venous in nature</li>\n<li>Commonly from DVT.</li>\n<li>Travel through large veins, through the right side of the heart and then get trapped in pulmonary arterial vasculatire.<ul>\n<li>Single embolus can straddle pulmonary artery bifurcation (saddle embolus)</li>\n<li>Can lodge in a pulmonary artery main branch and cause one-sided disease</li>\n<li>Most frequently, one or both sides of the lungs get small emboli that lodge in the smallest arterioles possible</li>\n<li><strong>Patients who have had one PE are at high risk for having another</strong></li>\n</ul>\n</li>\n<li>`&gt;60% ovvlusion can cause cardiovascular collapse.</li>\n<li>Can lead to pulmonary hemorrhage, but not usually infarction</li>\n<li>Small end-arterioles pulm. branches don’t usually hemorrhage or infarct.</li>\n<li>Multiple small emboli (over time) can cause pulmonary hypertension and right sided heart failure</li>\n</ul>\n</li>\n<li>Systemic (thrombo-)embolus <em>Cause infarction typically</em><ul>\n<li>Usually defined as an embolus in arterial circulation. </li>\n<li>80% from <strong>intracardiac mural thrombi</strong>. Other causes include:<ul>\n<li>Valvular vegetation</li>\n<li>Paradoxical embolus (venous embolism that makes it to arterial circulation because of other cardiac defect)</li>\n<li>Aortic aneurysm</li>\n<li>Thrombus on ulcerated atherosclerotic plaque. </li>\n</ul>\n</li>\n<li>Emboli in arteries most likely lodge in the lower extremities (75%) and brain (10%), with theintestines, kidneys, spleen and upper extremities also affected.</li>\n</ul>\n</li>\n<li>Fat and Marrow Embolism<ul>\n<li>After injury there can be a rupture of soft tissue venules or marrow vascular sinusoids.</li>\n<li>Adipose tissue or bone marrow can herniate into the intravascular space and travel to lungs and get lodged.<ul>\n<li>Fracture of long bones: 90% of severe skeletal injuries lead to embolism, but only 10% have symptoms.</li>\n<li>Soft tissue Trauma</li>\n<li>Burns</li>\n<li><strong>Vigorous cardiopulmonary resuscitation</strong>:</li>\n</ul>\n</li>\n<li><strong>Fat Embolism Syndrome</strong> is a situation where these types of embolism ARE symptomatic.<ul>\n<li>After 1-3 days patient experience pulmonary insufficiency, neuro symptoms, anemia, thrombocytopenia and a diffuse petechial rash.</li>\n<li>This can be fatal in 5-15% of paitents.</li>\n</ul>\n</li>\n<li>Air embolism: <ul>\n<li>More than 100cc of air is enough to have a clinical effect on pulmonary circulation.</li>\n<li>Volumes smaller than that can be catastrophic if introduced into coronary circulation.<ul>\n<li>ie. during a coronary bypass surgery.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Decompression Sickness<ul>\n<li>Bends - gas bubbles in skeletal muscles</li>\n<li>Chokes - respiratory distress caused by pulmonary gas emboli. Leads to edema, hemorrhage, and emphysema:</li>\n<li>Caisson disease - chronic decompression condition. Persistence of gas emboli in skeletal system leads to multpile foci of ischemic necrosis<ul>\n<li>Mainly seen in femoral head, tibia, and humeri.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Amniotic Fluid Embolism:<ul>\n<li>Squamous cells, fat, or mucin make it to pulmonary vasculature</li>\n<li>Severe respiratory compromise (dyspnea and cyanosis)</li>\n<li>followed by Neuro impairment (headache, seizure, coma)</li>\n<li>Finally disseminated intravascular coagulation (DIC).<pre><code>Incidence is 1 in 40,000 deliveries\nMortality is 80%, making it the fifth most common cause of maternal mortality\nworldwide\nCauses 10% of the maternal deaths in the US\n85% of patients that survive have neurologic deficits</code></pre></li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n",
            "image": "https://BGASM.github.io/medNotes/media/posts/6/Myelolipoma_histology_HE.jpg",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-11-30T22:19:09-05:00",
            "date_modified": "2020-12-03T00:32:08-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html",
            "url": "https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html",
            "title": "Adrenergic and Cholinergic Systems II",
            "summary": "Direct Adrenergic Stimulants (agonists)Organization:Adrenergic Stimulants (Sympathomimetics)A1 Agonist:A2 Agonists:B1 and B2 agonist:B3 agonist:Direct Adrenergic Stimulants (agonists)Factors that influence response to cholinergic and adrenergic drugs:Physical chemical propertiesRoute of administration and the pharmacokinetic properiesLocalization density and proportion of receptorAffinity for receptor subtypesCompensatory reflexesReceptor desensitizationDisease StateAgeOrganization:Drugs acting on adrenergic&hellip;",
            "content_html": "<ul>\n<li><a href=\"#-direct-adrenergic-stimulants-agonists\">Direct Adrenergic Stimulants (agonists)</a></li>\n<li><a href=\"#-organization\">Organization:</a></li>\n<li><a href=\"#-adrenergic-stimulants-sympathomimetics\">Adrenergic Stimulants (Sympathomimetics)</a></li>\n<li><a href=\"#---a1-agonists\">A1 Agonist:</a></li>\n<li><a href=\"#---a2-agonists\">A2 Agonists:</a></li>\n<li><a href=\"#---b1-and-b2-agonist\">B1 and B2 agonist:</a></li>\n<li><a href=\"#---b3-agonist\">B3 agonist:</a></li>\n</ul>\n<h2 id=\"direct-adrenergic-stimulants-agonists\">Direct Adrenergic Stimulants (agonists)</h2>\n<hr>\n<ul>\n<li>Factors that influence response to cholinergic and adrenergic drugs:<ul>\n<li>Physical chemical properties</li>\n<li>Route of administration and the pharmacokinetic properies</li>\n<li>Localization density and proportion of receptor</li>\n<li>Affinity for receptor subtypes</li>\n<li>Compensatory reflexes</li>\n<li>Receptor desensitization</li>\n<li>Disease State</li>\n<li>Age</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"organization\">Organization:</h2>\n<hr>\n<ul>\n<li>Drugs acting on adrenergic systems:</li>\n<li>Peripheral (Sympathetic) and Central</li>\n<li>Adrenergic stimulants: Mimetics<ul>\n<li>Direct</li>\n<li>Indirect</li>\n<li>Both</li>\n</ul>\n</li>\n<li>Adrenergic Blockers: Lytics<ul>\n<li>Direct</li>\n<li>Indirect<h2 id=\"adrenergic-stimulants-sympathomimetics\">Adrenergic Stimulants (Sympathomimetics)</h2>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li><p>Direct - Direct drugs mimic catecholamines as selective or non-selective. This is referring to therapeutic doses. In high concentration above the TD, drugs may lose selectivity.</p>\n<ul>\n<li><p>Adrenergic Receptor Agonists:</p>\n<ul>\n<li>Alpha 1 and 2</li>\n<li>Beta 1, 2, 3</li>\n<li>All coupled to G protein<ul>\n<li>Metabotropic</li>\n<li>Use of second messengers</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"adrenergic-system-recap\">Adrenergic System Recap:</h3>\n<hr>\n<ul>\n<li>Sympathetic come from thoraco-lumbar region</li>\n<li>Organized mainly in paravertebral ganglion</li>\n<li>Pre-gang neuron uses ACh to communicate with post-gang neuron</li>\n<li>Post-gang releases 80% NE, and only 20% Epi.</li>\n<li>Fight or Flight<ul>\n<li>Tachycardia, bronchodilation, vasoconstriction in most vessels</li>\n<li>Vasodilation in SOME vessels, such as those supplying skeletal muscles</li>\n</ul>\n</li>\n<li>Dopamine is released to control renal vascular tone, but not a primary catecholamine.</li>\n<li>Adrenal gland acts as like a post-ganglion neuron.<ul>\n<li>It releases 80% epinephrine, 20% NE &lt;&lt;&lt; Different than normal neurons.</li>\n</ul>\n</li>\n<li>CNS is mostly affected by NE.<ul>\n<li>Attention, alertness, concentration, energy, reduce appetite, sex drive.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"therapeutic-indication-of-ne\">Therapeutic Indication of NE:</h3>\n<hr>\n<ul>\n<li>Treat cardiogenic shock (IV)<ul>\n<li>Increase total peripheral resistance.</li>\n<li>Increase diastolic and systolic blood pressure during cardiogenic shock.</li>\n<li>Poor oral bioavailability. Quikcly inactivated by COMT and MAO in the liver and gut.</li>\n<li>Short action duration because it is matbolized.</li>\n<li>Lack of selectivity.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"therapeutic-indications-of-epi\">Therapeutic Indications of Epi:</h3>\n<hr>\n<ul>\n<li>Rapid relief of anaphylaxis reactions</li>\n<li>Prolong the effect of local anesthetics (alpha 1)</li>\n</ul>\n</li>\n<li><p><strong>Ceases bleeding (hemostatic agent) (alpha1→ vasoconstriction)</strong></p>\n</li>\n<li><p>Beneficial for asthma</p>\n<ul>\n<li>B2: decrease in antigen-induced inflammatory mediator release</li>\n<li>a1: decrease in bronchial secretion and congestion in mucosa</li>\n<li><strong>B2: Increases bronchodilation</strong></li>\n</ul>\n</li>\n<li><p>Adverse Effects:</p>\n<ul>\n<li>CNS: Anxiety and restlesness</li>\n<li>PNS:<ul>\n<li>Increase in physiological tremor (B2)</li>\n<li>Palpitations (B1)</li>\n<li>Increase blood sugar (A2)</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"selectivity\">Selectivity</h3>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Relative affinity: Epinephrine typically has a higher affinity for adrenergic receptors<ul>\n<li>A1: Epi &gt; NE</li>\n<li>A2: Epi &gt; NE</li>\n<li>B1: NE= Epi</li>\n<li>B2: Epi &gt;&gt;NE</li>\n<li>B3: NE &gt; Epi</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"a1-agonists\">A1 Agonists:</h2>\n<hr>\n<ul>\n<li><h3 id=\"phenylephrine\">Phenylephrine:</h3>\n<ul>\n<li>Pharmacokinetics: within therapeutic doses it does not cross the BBB.<ul>\n<li>Only metabolized by MAO. Not by COMPT. Higher Bioavail than epi.</li>\n<li>Pharmacodynamics: Selective for A1-adrenergic agonist</li>\n<li>Therapeutic Uses: are related with vasoconstriction<ul>\n<li><strong>Nasal decongestant</strong></li>\n<li>Maintain BP during anesthesia</li>\n<li>Cause contraction in radial muscle</li>\n<li>Contraction in pupils - Mydriassis</li>\n</ul>\n</li>\n<li>Adverse Effects:<ul>\n<li>Excess vasoconstriction</li>\n<li>Insomnia</li>\n<li><strong>Rebound nasal congestion</strong><ul>\n<li>After three days the therapeutic affect drops, and congestion rebounds severely.</li>\n</ul>\n</li>\n<li>May worsen prostatic hyperplasia</li>\n<li>Urinary bladder sphincter contraction</li>\n<li>Drug interactions:<ul>\n<li>MAO inhibitor will prolong</li>\n</ul>\n</li>\n<li><strong>Potential Systemic Problems:</strong><ul>\n<li>associated to BP, like hypertension and <strong>reflex bradycardia</strong></li>\n<li>BP = CO * TPR</li>\n<li>High % A1 receptors in these vessels.</li>\n<li>Agonist causes vascular contraction, which increases BP.</li>\n<li>To react to the increased BP, CO decreases, causing bradycardia.</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"midodrine\">Midodrine:</h3>\n<ul>\n<li>Therapeutic Use related with Vasoconstriction<ul>\n<li><strong>Orthostatic hypotension</strong></li>\n</ul>\n</li>\n<li>Adverse Effects due to A1 Stimulation<ul>\n<li>Vasoconstriction = hypertension</li>\n<li><strong>Contraction in urinary bladder sphincter = Urinary retention</strong></li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h2 id=\"a2-agonists\">A2 Agonists:</h2>\n<hr>\n<pre><code>  - Coupled to Gi proteins, which are inhibitory\n  - Decrease in NT release\n  - Decrease insulin secretion from Pancreatic B cells.\n  - Decreased sympathetic nerve activity due to brainstem (CNS) adrenoreceptors\n  - Increase aqueous outflow of humor in the eyes.</code></pre><ul>\n<li><h3 id=\"clonidine-central-acting-adrenergic-agonist\">Clonidine: Central Acting Adrenergic Agonist</h3>\n<ul>\n<li>Good bioavailability and crosses BBB, reaching the A2 receptors in the brainstem.</li>\n<li><strong>Reduce Adrenergic discharge of norepinephrine</strong></li>\n<li>Therapeutic Uses:<ul>\n<li><strong>Reduce Hypertension</strong>, withdrawal symptoms.</li>\n</ul>\n</li>\n<li>Adverse Effects:<ul>\n<li>Dry mouth, fatigue</li>\n<li><strong>Orthostatic Hypotension (old patients may fall)</strong></li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"apraclonidine-and-brimonidine\">Apraclonidine and Brimonidine:</h3>\n<ul>\n<li>Topical Intraocular administration</li>\n<li>Treat decrease pressure caused  accumulation of aqueous outflow.</li>\n<li>Therapeutic Use:<ul>\n<li>Open-angle glaucome</li>\n</ul>\n</li>\n<li>Adverse Effect:<ul>\n<li>Orthostatic hypotension caused if drug reaches systemic circulation</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"methyldopa\">Methyldopa:</h3>\n<ul>\n<li>Prodrug. Distribution throughout the body (placenta, BBB)</li>\n<li>CNS mainly. Causes a reduction in the release of NE from CNS</li>\n<li>Decrease sympathetic tone, which decreases total peripheral resistance.</li>\n<li>Therapeutic Use:<ul>\n<li>Decrease hypertension</li>\n<li><strong>Drug of choice for hypertension during pregnancy and breastfeeding</strong></li>\n<li></li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h2 id=\"b-1-adrenergic-receptor-agonist\">B-1 Adrenergic Receptor Agonist:</h2>\n</li>\n</ul>\n<hr>\n<pre><code>  - Increased Heart Rate: Positive chronotropic effect\n  - Increase force: Positive inotropic effect\n  - Increase automaticity: Positive dromotropic effect\n  - Increased Cardiac Output:\n  - Dobutamine, Dopamine (mostly cardio-stimulatory effects)</code></pre><ul>\n<li><h3 id=\"dopamine\">Dopamine</h3>\n<ul>\n<li>PK: Very short acting (substrate for transporters and enzymes)</li>\n<li>Dose dependent.</li>\n<li>Therapeutic EffecT: Moderate Dose<ul>\n<li>Severe congestive heart failure</li>\n<li>Cardiogenic shock with hypotension</li>\n</ul>\n</li>\n<li>Low Dose:<ul>\n<li><strong>Increase renal blood floow. DA1 agonist in kidneys</strong></li>\n<li>Cause vomiting D2 in CNS.</li>\n</ul>\n</li>\n<li>High Dose:<ul>\n<li>A1 agonist. Increases peripheral vascular resistance: cardiac output, heart rate</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><h3 id=\"dobutamine\">Dobutamine:</h3>\n<ul>\n<li>PK: Short duration, IV adm.</li>\n<li>Only stimulate B1 receptors</li>\n<li>Positive inotropic drug</li>\n<li>Small amount of vasoconstriction due to A1-agonism</li>\n<li>Therapeutic:<ul>\n<li>Drug of choice to treat cardiogenic shock</li>\n</ul>\n</li>\n<li>Does not cause vomiting or increase renal blood flow.</li>\n<li>Can cause tachycardia.<ul>\n<li><h2 id=\"b-2-adrenergic-receptor-agonist\">B-2 Adrenergic Receptor Agonist:</h2>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<pre><code>  - Smooth muscle relaxation\n  - Some blood vessels: vasodilation\n      - Skeletal, liver, heart, coronary\n  - Glycogenolysis, gluconeogenesis\n  - Increase insulin release from pancreas.\n  - Mast cells decrease histamine release.\n  - Adrenergic neurons increase NE release.</code></pre><ul>\n<li><strong>SABA - Short Acting Beta Agonist</strong>    <pre><code> - Abuterol, Terbutaline - SABA\n - Fast onset and offset.</code></pre></li>\n<li><strong>LABA - Long Acting Beta Agonist</strong><pre><code> - Formoterol - fast onset\n - Salmeterol - slow onset</code></pre><ul>\n<li>Effect of B2 activation<ul>\n<li>Bronchorelaxation</li>\n<li>Reduction of airway inflammation</li>\n<li>Reduction of episodic bronchospasms due to allergens</li>\n</ul>\n</li>\n<li>Therapeutic Use: Asthma and COPD<ul>\n<li><strong>Terbutaline is used as off-label to delay premature labor.</strong></li>\n</ul>\n</li>\n<li>Adverse Effect:<ul>\n<li>Tremor</li>\n<li>Tachycardia</li>\n<li><strong>Insulin secretion. - Terbutaline</strong><ul>\n<li><h2 id=\"b1-and-b2-agonist\">B1 and B2 agonist:</h2>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li><h3 id=\"isoproterenol\">Isoproterenol:</h3>\n<ul>\n<li>Target organs:<ul>\n<li>Heart - B1</li>\n<li>Lungs - B2</li>\n</ul>\n</li>\n<li>PK: Metabolized by liver (COMT): brief duration of action</li>\n<li>Effects:<ul>\n<li>Stimulate heart (B1)</li>\n<li>Vasodilator - vessels that irrigate skeletal muscle(B2)</li>\n<li>Bronchodilation (B2)</li>\n</ul>\n</li>\n<li>Therapeutic:<ul>\n<li>Rarely used</li>\n<li>Heart block to stimulate heart B1 and management is asthma/bronchitis B2</li>\n</ul>\n</li>\n<li>Adverse effect: Tachycardia, headache, flushing</li>\n<li><h2 id=\"b3-agonist\">B3 agonist:</h2>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li><h3 id=\"mirabegron\">Mirabegron</h3>\n<ul>\n<li>Affect:<ul>\n<li>Endogenous B3 Agonist Activate lipolysis in fat cells. </li>\n<li><strong>The Mirabegron drug does NOT have the effect.</strong></li>\n<li><strong>Detrusor muscle relaxation</strong> in smooth muslce tissue of the urinary bladder</li>\n</ul>\n</li>\n<li>B3 receptor in detrusor muscle in bladder. Couple to Gi protein, so has inhibitory affect, which relaxes the muscle. It allows storage of more urine.</li>\n<li>Therapeutic:<ul>\n<li>Treat symptoms of frequent or urgent urination and incontinence due to overactive bladder (OAB).</li>\n</ul>\n</li>\n<li>PK: Good bioavailabilty, no BBB crossing</li>\n<li>AE: <strong>Urinary</strong> retention, Tachycardia, Tremor</li>\n<li>Non-Selective</li>\n</ul>\n</li>\n</ul>\n",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-11-30T22:17:39-05:00",
            "date_modified": "2020-12-02T23:06:50-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html",
            "url": "https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html",
            "title": "Edema Congestion and Hemostasis",
            "summary": "Congestion and Hyperemia:HemostasisBleeding or Hypercoagulable state:Platlet vs Coagulation Cascade: Qualitative vs QuantitativeEdema60% bodyweight is water, 2/3 which is intracellular. Transudate Exudate Remeber that inflammatory edema makes sense. Inflammation leads to vascular permeability/dilation. This hyperemia allows fluid to leave vessels and settle, causing edema.Increased hydrostatic pressure&hellip;",
            "content_html": "<ul>\n<li><a href=\"#congestion-and-hyperemia\">Congestion and Hyperemia:</a></li>\n<li><a href=\"#hemostasis\">Hemostasis</a><ul>\n<li><a href=\"#-bleeding-or-hypercoagulable-state\">Bleeding or Hypercoagulable state:</a></li>\n<li><a href=\"#-platlet-vs-coagulation-cascade-qualitative-vs-quantitative\">Platlet vs Coagulation Cascade: Qualitative vs Quantitative</a></li>\n</ul>\n</li>\n</ul>\n<h1 id=\"edema\">Edema</h1>\n<ul>\n<li><p>60% bodyweight is water, 2/3 which is intracellular.</p>\n<ul>\n<li>Of the remaining water, 35% is in extracellular space. AKA interstitial fluid and ‘third spaces’<ul>\n<li>Third space is not quite interstitial, its like the cavities of the pleual or abdominal cavities, the pericardial sac. And fluid does collect in these spaces.</li>\n</ul>\n</li>\n<li>There is a balance of vascular hydrostatic pressure against plasma colloid osmotic pressure.<ul>\n<li>Hydrostatic is always a little higher, because fluid needs to escape the vessel and reach lymphatics.</li>\n<li>While RBCs die, we will also keep fluid moving overall.  </li>\n</ul>\n</li>\n</ul>\n<p>Transudate</p>\n<ul>\n<li>Protein and cell poor edema that is caused by an increase in hydrostatic pressure, or a reduction in plasma proteins.  </li>\n<li>It is common in organ failure and malnutrition.  </li>\n<li>Appears clear or amber.  </li>\n</ul>\n</li>\n</ul>\n<p> Exudate</p>\n<ul>\n<li>Protein and cell rich edema that is caused by inflammation.  </li>\n<li>It is one of the outcomes caused by the cascade of inflammatory-induced events (vascular permeability, cellular response.)  </li>\n<li>Fluid appears amber or cloudy.</li>\n</ul>\n<h2 id=\"edema-names\">Edema Names:</h2>\n<hr>\n<ul>\n<li>Anasarca: Whole-body generalized and severe edema with subcutaneous tissue swelling.  </li>\n<li>Serous: A transudate or light exudate with mainly edema fluid.  </li>\n<li>Serosanguinous: Effusion with RBC.  </li>\n<li>Fibrinous: Fibrin strans that bridge from heart and pericardial sac and are derived from a protein rich exudate.  </li>\n<li>Purulent: Exudate with numerous neutrophils. ALso called empyema in pleural space.  </li>\n</ul>\n<h2 id=\"severity\">Severity:</h2>\n<hr>\n<ul>\n<li>Edema can range from having minimal to life threatening consequences.</li>\n<li>Subcutaneous can be a bite or a blister, or it can signal systemic cardiac or renal disease.</li>\n<li>Localized edema can inhibit wound healing, prevent clearing pathogens, or cause a physical obstruction.</li>\n<li>Pulmonary edema can be caused by several clinical scenarious, and it can be life threatening.</li>\n<li>Cerebral edema can also be fatal, as it developes rapidly and can cause the brain to herniate.</li>\n</ul>\n<h2 id=\"morphology\">Morphology:</h2>\n<hr>\n<ul>\n<li>Pitting Edema:<ul>\n<li>Subcutaneous:<ul>\n<li>Appears swollen, shiny and boggy</li>\n<li>Compression artifact that resolves slowly.</li>\n<li>Gravity and hydrostatic pressure cause <strong>dependent edema</strong> in the legs when standing or sacrum with prone.</li>\n<li>Linked with Right heart failure<ul>\n<li>Poor blood return. Blood backs up into vena cava and edema builds up in lowed extremities.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Pulmonary:<ul>\n<li>Heavy wet lungs.</li>\n<li>Frothy, blood-tinged fluid expressed when compressing parenchyma.</li>\n</ul>\n</li>\n<li>Cerebral:<ul>\n<li>Generalized or local swelling.</li>\n<li>Expanded gyri, narrowed sulci</li>\n<li>Herniation of brain or brainstem</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<h2 id=\"pathophysiology-of-non-inflammatory-edema\">Pathophysiology of Non-Inflammatory Edema:</h2>\n<hr>\n<pre><code> Remeber that inflammatory edema makes sense. \n Inflammation leads to vascular permeability/dilation.\n This hyperemia allows fluid to leave vessels and settle, causing edema.</code></pre><ol>\n<li>Increased hydrostatic pressure <strong>Usually Cardiac</strong><ul>\n<li>Can occur due as regional or systemic.</li>\n<li>Localized edema in one leg can lead to <strong>DVT</strong> which can cause a focal impairment of venous return.</li>\n<li>Generalized <strong>increases in venous pressure can also lead to systemic edema</strong>. Such as in congestive heart failure.</li>\n</ul>\n</li>\n<li>Reduced oncotic pressure due to inadequate plasma protein (albumin) <strong>Usually Hepatic</strong><ul>\n<li>Reduced albumin synthesis (<strong>liver disease</strong>), malnut</li>\n</ul>\n</li>\n<li>Primary sodium retention. <strong>Kidneys</strong></li>\n<li>Primary water retention</li>\n<li>Lymphatic obstruction leading to lymphedema.<ul>\n<li>Usually localized.</li>\n<li>Lymphedema in an extremity, usually upper arm, is seen commonly due to removal of or radiation to axiallary lymph nodes. <strong>Breast Cancer</strong></li>\n<li>Parasitic disease <strong>filariasis</strong> show extensive lower limb and genital edema.</li>\n</ul>\n</li>\n</ol>\n<h1 id=\"congestion-and-hyperemia\">Congestion and Hyperemia:</h1>\n<ul>\n<li><p>Occur when a vascular space is expanded.</p>\n</li>\n<li><p>Both result from <strong>locally increased blood volume</strong>.</p>\n</li>\n<li><p>Associated with increased intravascular pressures, which often lead to edema.</p>\n</li>\n<li><p><strong>Hyperemia</strong> is an active process. It is due to blood inflow from arterial dilation.</p>\n<ul>\n<li>Tissue becomes red and engorged with blood. <strong>Obvious when seen</strong></li>\n<li>Seen in skeletal muscle when exercising, or sites of inflammation.</li>\n</ul>\n</li>\n<li><p><strong>Congestion</strong> is a passive proocess due to impaired outflow of blood from tissue.</p>\n<ul>\n<li>Tissue are blue <strong>cyanotic</strong>  due to accumulation of deoxyhemoglobin.</li>\n<li>Over time, lack of oxygenated blood lead to localized hypoxia - which can eventually lead to ischemia and necrosis.</li>\n<li>Capillaries rupture. Lead to characterisitc <strong>hemosiderin-laden macrophages</strong></li>\n<li>Organ Specific Congestion has characteristic morphologic changes:<ul>\n<li>Chronic pulmonary congestion:<ul>\n<li>Alveolara septa get thick and fibrotic.</li>\n<li>Lots of the hemosiderin-laden macrophages (<strong>heart failure cells</strong>)</li>\n</ul>\n</li>\n<li>Chronic hepatic congestion:<ul>\n<li>Homorrhage within the lobes of the liver lead to a dumping-out of the hemosiderin-laden macrophages and hepatocytes.</li>\n<li>These cells undergo ischemia and necrosis and they make the liver look mottled, red-brown, and depressed.<ul>\n<li><strong>Nutmeg Liver</strong><h1 id=\"hemostasis\">Hemostasis</h1>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n<li><p>Sequence of Events:</p>\n<ol>\n<li>Following injury <strong>vasoconstriction</strong> limits blood flow in the area. Vasoconstriction is transient and augmented by endothelial cell endothelin.</li>\n<li>Exposed <strong>extracellular matrix is thrombogenic</strong>. Induces reaction that causes <strong>adherence and activateion of platelets</strong> in order to form a <strong>hemostatic plug</strong>.</li>\n<li>Endothelial cells release tissue factor (<strong>factor III or thromboplastin</strong>) which works iwht factor VII to initiate <strong>coagulation</strong>. Thrombin gets generated at the site and cleaves <strong>fibrinogen into fibrin</strong>. Forms a fibrin mesh and this is secondary hemostasis.</li>\n<li>Fibrin and platelet aggregates form a stable plug. Counter processes to stop and revers thrombus formation.  </li>\n</ol>\n</li>\n</ul>\n<h3 id=\"bleeding-or-hypercoagulable-state\">Bleeding or Hypercoagulable state:</h3>\n<hr>\n<ul>\n<li><strong>Bleeding State</strong></li>\n<li>Bernard-Soulier Syndrome GP1B.</li>\n<li>Von Willibrand disease due to too little or too weak vWF.</li>\n<li>Glanzmaan thromoasthenia due to deficiency in GpIIa-IIIb.  </li>\n</ul>\n<h3 id=\"platlet-vs-coagulation-cascade-qualitative-vs-quantitative\">Platlet vs Coagulation Cascade: Qualitative vs Quantitative**</h3>\n<hr>\n<ul>\n<li>Platelet Tests:<ul>\n<li>Qualitative: Bleed time</li>\n<li>Quantitative: Platelets are measured and counted.</li>\n</ul>\n</li>\n<li>Coagulation Tests:<ul>\n<li>Activated Partial Thromboplastin Time - aPPT</li>\n<li>Prothrombin Time - PT.  </li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Normal endothelium supports a state of anti-coagulation. If there is an injury we flip things up.<ul>\n<li>von WIllibrong Factor (GP1B receptor - deficiency is called Bernard-Soulier syndrome)</li>\n<li>Tissue factor: Ectivates extrinsic pathway in response to TNF.</li>\n<li>Plasminogen activator inhibitors: Favor thrombosis</li>\n</ul>\n</li>\n</ul>\n",
            "image": "https://BGASM.github.io/medNotes/media/posts/3/Myelolipoma_histology_HE.jpg",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-11-30T12:26:10-05:00",
            "date_modified": "2020-11-30T22:17:57-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html",
            "url": "https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html",
            "title": "Adrenergic and Cholinergic III",
            "summary": "Indirect Adrenergic Mimicking drugsMAO Inhibitors - Phenelzine and SelegilineCOMT Inhibitors - Entacapone, Levodopa, CabidopaReuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, DextroamphetamineReuptake Inhibitors - DAT and NET: CocaineReuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)Releasing agent: Tyramine:Mixed Adrenergic Mimicking DrugsMethylphenidate /&hellip;",
            "content_html": "<ul>\n<li><a href=\"#-indirect-adrenergic-mimicking-drugs\">Indirect Adrenergic Mimicking drugs</a><ul>\n<li><a href=\"#-mao-inhibitors---phenelzine-and-selegiline\">MAO Inhibitors - Phenelzine and Selegiline</a></li>\n<li><a href=\"#-comt-inhibitors---entacapone-levodopa-cabidopa\">COMT Inhibitors - Entacapone, Levodopa, Cabidopa</a></li>\n<li><a href=\"#-reuptake-inhibitors---net-amphetamine-methamphetamine-lisdexamphetamine-dextroamphetamine\">Reuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, Dextroamphetamine</a></li>\n<li><a href=\"#-reuptake-inhibitors---dat-and-net-cocaine\">Reuptake Inhibitors - DAT and NET: Cocaine</a></li>\n<li><a href=\"#-reuptake-inhibitors---net-and-5ht-imipramine-desipramine-amitriptyline-nortriptyline-tricyclic-antidepressants-tca\">Reuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)</a></li>\n<li><a href=\"#-releasing-agent-tyramine\">Releasing agent: Tyramine:</a></li>\n</ul>\n</li>\n<li><a href=\"#-mixed-adrenergic-mimicking-drugs\">Mixed Adrenergic Mimicking Drugs</a><ul>\n<li><a href=\"#---methylphenidate--dextroamphetamine\">Methylphenidate / Dextroamphetamine</a></li>\n<li><a href=\"#---pseudophedrin\">Pseudophedrin</a><ul>\n<li><a href=\"#summary-of-therapeutic-uses-of-indirect-and-mixed\">Summary of Therapeutic Uses of Indirect and Mixed</a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li><a href=\"#notes\">Notes</a><ul>\n<li><a href=\"#questions-34353946474969\">Questions: 34;35;39;46;47;49;69.</a><h3 id=\"indirect-adrenergic-mimicking-drugs\">Indirect Adrenergic Mimicking drugs</h3>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Enzyme inhbitors: MAO, COMT, DD (dopamine decarboxylase)<ul>\n<li>MAO:<ul>\n<li>Phenelzine</li>\n<li>Selegiline</li>\n</ul>\n</li>\n<li>COMT:<ul>\n<li>Entacapone</li>\n</ul>\n</li>\n<li>DD:<ul>\n<li>Carbidopa</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Uptake inhibitors: NET, DAT<ul>\n<li>NET:<ul>\n<li>Amphetamine</li>\n<li>Methamphetamine</li>\n</ul>\n</li>\n<li>DAT and NET:<ul>\n<li>Cocaine</li>\n<li>Methylphenidate</li>\n</ul>\n</li>\n<li>NET and 5HT:<ul>\n<li>Imipramine</li>\n<li>Desipramine</li>\n<li>Amitriptyline</li>\n<li>Nortiptyline</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Releasing agent:<ul>\n<li>Tyramine: Not a drug, but does interfere.<h3 id=\"mao-inhibitors---phenelzine-and-selegiline\">MAO Inhibitors - Phenelzine and Selegiline</h3>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>When catecholamines and 5HT are taken up, they are inactivated by MAO or COMPT. (Tissue more COMPT, Nerve ending more MAO)</li>\n<li>This takes place before storage of NT. They get inactivated before storage.</li>\n<li>MAO-A and MAO-B. Both cause irreversible inhibition of MAO.<ul>\n<li>MAO-A is not selective</li>\n<li>MAO-B is selevtive for dopamine.</li>\n<li>Phenelzine inhibits MAO-A and MAO-B<ul>\n<li>Increase in NE, DA, 5HT</li>\n</ul>\n</li>\n<li>Selegiline inhibits MAO-B<ul>\n<li>Increase in DA.</li>\n</ul>\n</li>\n<li>Therapeutic Use:<ul>\n<li>Depression: Phenelzine</li>\n<li>Parkinson: Selegiline (disease with low levels of Dopa.) <h3 id=\"comt-inhibitors---entacapone-levodopa-cabidopa\">COMT Inhibitors - Entacapone, Levodopa, Cabidopa</h3>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Dopamine is mostly made in CNS.<ul>\n<li>If dopamine is not stored it can be inactivated by COMT</li>\n<li>Dopamine is a norepi precursor. It cannot cross the BBB.<ul>\n<li>This means that if there is degeneration of Dopamine production in the brain, peripheral Dopamine cannot rescue it because it cannot cross BBB.</li>\n<li>L-DOPA can cross the BBB, but COMT and DD quickly degrade it.</li>\n<li>Treatment revolves around inhibiting COMT and DD so that L-DOPA can cross the BBB.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Entacapone:<ul>\n<li>Drug that inhibits COMT. This enhances the conversion of L-DOPA to DA.</li>\n<li>No effect on DD, so efficacy is fairly low.</li>\n<li>Drug has low CNS penetration, so it will not have effect on the brain.</li>\n<li>We combine with Levodopa, which is not an inhibitor of any of these enzyme on its own.</li>\n</ul>\n</li>\n<li>Levodopa:<ul>\n<li>Not an enzyme inhibitor.</li>\n<li>Levodopa enhances the effect of Entacapone.</li>\n<li>Levodopa can cross the BBB.</li>\n<li>It is similar (synthetic) to L-Dopa, so it saturates COMT and DD in the CNS.</li>\n<li>This allows for more L-Dopa to cross BBB and get converted to DA.</li>\n</ul>\n</li>\n<li>Carbidopa:<ul>\n<li>DD inhibitor.</li>\n<li>Unable to cross BBB.</li>\n<li>Can be combined with Levodopa again.</li>\n<li><strong>Carbidopa + Levodopa is the Gold Standard for Parkinsons Disease</strong><h3 id=\"reuptake-inhibitors---net-amphetamine-methamphetamine-lisdexamphetamine-dextroamphetamine\">Reuptake Inhibitors - NET: Amphetamine, Methamphetamine, Lisdexamphetamine, Dextroamphetamine</h3>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li><p>Amphetamine, Methamphetamine:</p>\n<ul>\n<li><p>Liposoluble, good bioavailability, long duration of action.</p>\n</li>\n<li><p>Penetrate the BBB</p>\n</li>\n<li><p>MoA is Inhibition of Norepinephrine Transporter - NET.</p>\n<ul>\n<li>Blocks uptake of Norepi, allowing it to accumulate in the synaptic cleft and continue its action.</li>\n<li>Also enters nerve through NET and transports into vesicles through VMAT.</li>\n<li>This causes Norepinephrine to displace out from the vesicle, where it can be released through reverse transport!</li>\n</ul>\n</li>\n<li><p>Overall effect of NET inhibition is an  ↑↑↑ of NE in the cleft, so an enhanced stimulant action.</p>\n</li>\n<li><p>Peripheral: B1 and A1 primarily</p>\n<ul>\n<li>Tachycardia (B1)</li>\n<li>Vasoconstriction (A1)</li>\n</ul>\n</li>\n<li><p>Therapeutic:</p>\n<ul>\n<li>Treat narcolepsy, ADHD, Binge eating</li>\n</ul>\n</li>\n<li><p>Adverse:</p>\n<ul>\n<li>CNS stimuli: jitters, <strong>insomnia, anorexia</strong>, seizures, hallucination, paranoia.</li>\n<li>PNS: headace, <strong>tachyarrhytmias, hypertension</strong>/hypotension, sweating, nausea, diarrhea,<h3 id=\"reuptake-inhibitors---dat-and-net-cocaine\">Reuptake Inhibitors - DAT and NET: Cocaine</h3>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Cocaine:<ul>\n<li>Penetrates BBB</li>\n<li>MoA: DAT and NET inhibition. This increases the amount of both NE and DA in the synaptic cleft and therefore enhance the stimulant action of both.</li>\n<li>In particular, it inhibits the reuptake in pleasure centers of CNS.<ul>\n<li>Sympathomimetic effect in PNS. The reuptake is also blocked in PNS, but its less exciting.</li>\n</ul>\n</li>\n<li>Therapeutic:<ul>\n<li>Pretty limited. Only used as a local anesthetic.</li>\n<li>No systemic effect. Only used topically (damn, not even orally)</li>\n<li>Combine anesthetic and vasoconstriction (sympathomimetic)</li>\n</ul>\n</li>\n<li>Adverse effects:<ul>\n<li>Sudden death (<strong>cardiac and respiratory arrest</strong>). </li>\n<li>Non-fatal effects: <strong>agitation, paranoia, tachycardia and hypertension</strong>, seizures, angina pectoris/myocardial ischemia, and hyperthermia.</li>\n<li>Repeated “snorting” can result in chronic rhinitis, cartilaginous necrosis, sinusitis, and <strong>nose bleeds</strong>.<h3 id=\"reuptake-inhibitors---net-and-5ht-imipramine-desipramine-amitriptyline-nortriptyline-tricyclic-antidepressants-tca\">Reuptake Inhibitors - NET and 5HT: IMIPRAMINE, DESIPRAMINE, AMITRIPTYLINE, NORTRIPTYLINE: Tricyclic Antidepressants (TCA)</h3>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Tricyclic Antidepressants (TCA)<ul>\n<li>Inhibit the Norepinephrine transporter at pre-synaptic terminals in the CNS</li>\n<li>Also inhibit the 5-HT transporters.</li>\n<li>Both NE and 5HT accumulate in synaptic cleft, and mostly in CNS, so they stimulate the mood.</li>\n<li>Therapeutic:<ul>\n<li>Used to treat depression, peripheral neuropathy, and chronic pain.</li>\n</ul>\n</li>\n<li>Additional Mechanism:<ul>\n<li>Antagonist of serotonergic, A1, histamine, and muscarinic receptors.</li>\n<li>These could potentially lead to adverse effects.</li>\n</ul>\n</li>\n<li>Adverse Effects:<ul>\n<li>CNS: Confusion and hallucinations (antimuscarininc)</li>\n<li>Periphery: <ul>\n<li>Postural hypotension (orthostatic) due to A1-adrenergic antagonism.</li>\n<li>Atropine-like effects (antimuscarinic)</li>\n<li>Sinus tachycardia, urinary retnetion, dry <strong>mouth</strong> (due to antimuscarinic).<h3 id=\"releasing-agent-tyramine\">Releasing agent: Tyramine:</h3>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Not a drug, but plays a role in drug interaction.<ul>\n<li>Endogenous by-product of tyrosine metabolism. The amount of tyramine generated endogenously is not significant (only traces).</li>\n<li>Found in high concentrations in some fermented foods (<strong>cheese, wine</strong>, etc..)</li>\n<li>When foods containing tyramine are ingested, <strong>tyramine is inactivated (metabolized) by MAO in the liver and GI tract</strong> (rapid first-pass metabolism). <ul>\n<li>Thus, normally, tyramine is not found in the systemic circulation.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Tyramine is not given to patients.<ul>\n<li>In animals when administered the effect was enhancing imipramine and amyitriptyline because tyramine releases catecholamines from nerve endings.</li>\n</ul>\n</li>\n<li>Route:<ul>\n<li>Tyramine gets absorbed in the gut and then the blood and gets taken up by sypathetic nerve endings through NET.</li>\n<li>Transported into vesicles by VMAT.</li>\n<li>Displaces NE from vesicles.</li>\n<li>Our patient is on MAO inhibitors, so there is no enzyme available to degrade the excess NE.</li>\n</ul>\n</li>\n<li><strong>Can cause a hypertensive crisis.</strong></li>\n</ul>\n<h3 id=\"mixed-adrenergic-mimicking-drugs\">Mixed Adrenergic Mimicking Drugs</h3>\n<hr>\n<ul>\n<li>Direct and Indirect, they are mixed:<ul>\n<li>Agonist on adrenergic causing release of NE and DA</li>\n<li>Amphetamine-like Compounds</li>\n<li>Methylphenidate / Dextroamphetamine: Schedule II</li>\n<li>Pseudophedrin: Over the Counter<h3 id=\"--methylphenidate--dextroamphetamine\">- Methylphenidate / Dextroamphetamine</h3>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Structural analogs of amphetamine<ul>\n<li>Mechanism: Indirectly <strong>inhibit DAT and NET</strong> as well as <strong>A1 agonist (vasoconstriction)</strong></li>\n<li>Consequence is an increase in the amount of NE and DA in synaptic clefts (both periphery and CNS)</li>\n<li>The NT’s are associated with learning and memory.</li>\n</ul>\n</li>\n<li>Therapeutic:<ul>\n<li>ADHD</li>\n</ul>\n</li>\n<li>Adverse Effects:<ul>\n<li>CNS: anorexia, dry mouth, anxiety, nausea, insomnia, agitation, irritability, dyskinesia, lethargy, dizziness, depression, emotional lability, confusion,</li>\n<li>Periphery: abdominal pain, tachycardia (reflex bradycardia), blurred vision (A1 agonism) and bruxism<h3 id=\"--pseudophedrin\">- Pseudophedrin</h3>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<ul>\n<li>Mechanism: <ul>\n<li>Indirect: inhibits NET and release of NE from vesicles </li>\n<li>Direct: A1 B1 agonist (low affinity for B2)</li>\n</ul>\n</li>\n<li>Consequence:<ul>\n<li>Inhibit NE reuptake and displaces NE from storage.</li>\n<li>Increase accumulation of NE in periphery and CNS<ul>\n<li>Similar to amphetamines, but less CNS stimulation.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Therapeutic:<ul>\n<li>Nasal decongestant</li>\n</ul>\n</li>\n<li>Adverse Effects:<ul>\n<li>Atrial fibrillation, reflex bradycardia, ventricular permature beats, hypertension, insomnia.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"notes\">Notes</h3>\n<ul>\n<li>Heteroreceptor<ul>\n<li>Receptors that are stimulated by agents other than catecholamines</li>\n</ul>\n</li>\n<li>Autoreceptor<ul>\n<li>Respond to NT’s released from their own nerve ending.</li>\n<li>Stimulation of these can inhibit further release</li>\n<li>A2 most common autoreceptor. Inhibit catecholamine release.</li>\n<li>B2 in pre-synaptic. Facilitates catecholamine release.</li>\n<li>A lot more A2 than B2.</li>\n</ul>\n</li>\n<li>Serotonin</li>\n<li>Pathway of Tyrosine to Catecholamine:<ol>\n<li>Tyrosine transported into the cell</li>\n<li>Converted into L-dopa by Tyrosine Hydroxylase</li>\n<li>L-Dopa converted to Dopamine by Dopa Decarboxylase DD </li>\n<li>Dopamine can be converted into NorEpi by Dopamine Beta Hydrozylase</li>\n<li>If not converted by DBH, then dopamine stored in vesicle by Vesicular Monoamine Transporter VMAT </li>\n</ol>\n</li>\n</ul>\n<h3 id=\"questions-34353946474969\">Questions: 34;35;39;46;47;49;69.</h3>\n",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-11-30T12:07:57-05:00",
            "date_modified": "2020-11-30T22:20:14-05:00"
        },
        {
            "id": "https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems.html",
            "url": "https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems.html",
            "title": "Adrenergic and Cholinergic Systems I",
            "summary": "Peripheral Nervous SystemDescribe the organizationCite primary neurotransmittersThe cholinergic autonomic neurons (ie, release acetylcholine)Describe synthesis, metabolism, storage, and termination of action of those neurotransmittersList respective receptors and subtypes. Describe the main transduction mechanisms and when the receptors are stimulated.NicotinicMuscarinicNoradrenergicAssociate target organs and physiological action when receptors&hellip;",
            "content_html": "<ol>\n<li><a href=\"#-peripheral-nervous-system\">Peripheral Nervous System</a><ul>\n<li><a href=\"#describe-the-organization\">Describe the organization</a></li>\n</ul>\n</li>\n<li><a href=\"#-cite-primary-neurotransmitters\">Cite primary neurotransmitters</a></li>\n<li><a href=\"#-the-cholinergic-autonomic-neurons-ie-release-acetylcholine-are\">The cholinergic autonomic neurons (ie, release acetylcholine)</a></li>\n<li><a href=\"#-describe-synthesis-metabolism-storage-and-termination-of-action-of-those-neurotransmitters\">Describe synthesis, metabolism, storage, and termination of action of those neurotransmitters</a></li>\n<li><a href=\"#-list-respective-receptors-and-subtypes-describe-the-main-transduction-mechanisms-and-when-the-receptors-are-stimulated\">List respective receptors and subtypes. Describe the main transduction mechanisms and when the receptors are stimulated.</a><ul>\n<li><a href=\"#nicotinic\">Nicotinic</a></li>\n<li><a href=\"#muscarinic\">Muscarinic</a></li>\n<li><a href=\"#noradrenergic\">Noradrenergic</a></li>\n</ul>\n</li>\n<li><a href=\"#-associate-target-organs-and-physiological-action-when-receptors-are-stimulated-consider-the-affinities-when-descrbing-norephedrine-and-epinephrine\">Associate target organs and physiological action when receptors are stimulated. Consider the affinities, when descrbing norephedrine and epinephrine.</a><ul>\n<li><a href=\"#list-effects-triggered-by-ach-and-catecholamines-ne-da-acting-on-the-cns\">List effects triggered by ACh and catecholamines (NE, DA), acting on the CNS.</a></li>\n<li><a href=\"#end-of-chapter-notes\">End of Chapter Notes:</a></li>\n<li><a href=\"#adrenergic-junctions\">Adrenergic Junctions</a></li>\n</ul>\n</li>\n</ol>\n<hr>\n<h3 id=\"peripheral-nervous-system\">Peripheral Nervous System</h3>\n<hr>\n<h3 id=\"describe-the-organization\">Describe the organization</h3>\n<ul>\n<li>Pre and postganglionic neurons</li>\n<li>Cell bodies of pre-gang in spinal cord</li>\n<li>Axons of post-gang mostly unmyelinated</li>\n<li>Somatomotor nervous system:  the neuron that leaves the spinal cord projects directly to the effector organ.</li>\n<li>Autonomic nervous system: synapse between the neuron that leaves the spinal cord and the effector organ <ul>\n<li>except for neurons that innervate the adrenal medulla </li>\n</ul>\n</li>\n<li>Note all neurons that leave the CNS release acetylcholine (ACh).</li>\n<li>Parasympathetic release ACh pre and post-gang.</li>\n<li>Sympathetic release ACh pre-gang, and then an adrenergic NT post-gang.</li>\n<li>Sympathetic in thoracolumbar &gt; Paravertebral Gang &gt; Effectors</li>\n<li>Parasympathetic is craniosacral &gt; Effector or Vagal Nerve &gt; Sacral &gt; Effector</li>\n</ul>\n<h3 id=\"cite-primary-neurotransmitters\">Cite primary neurotransmitters</h3>\n<hr>\n<ul>\n<li>ACh is neurotransmitter released by all neurons whose axons exit the CNS.<ul>\n<li>cranial motor neurons, α-motor neurons, γ-motor neurons, preganglionic sympathetic neurons, and preganglionic parasympathetic neurons</li>\n</ul>\n</li>\n<li>Post-gang parasympathetic neurons also release acetylcholine </li>\n<li>Post-gang sympathetic neurons release either norepinephrine, epinephrine or acetylcholine.<h3 id=\"the-cholinergic-autonomic-neurons-ie-release-acetylcholine-are\">The cholinergic autonomic neurons (ie, release acetylcholine) are</h3>\n</li>\n</ul>\n<hr>\n<ol>\n<li>All pregang neurons</li>\n<li>All parasympathetic postgang neurons</li>\n<li>Sympathetic postgang neurons innervate sweat glands</li>\n<li>Sympathetic postgang neurons ending on vessels skeletal muscles and produce vasodilation when stimulated (sympathetic vasodilator nerves).</li>\n</ol>\n<ul>\n<li>Remaining sympathetic postganglionic neurons are noradrenergic (ie, release norepinephrine). </li>\n<li>Adrenal medulla is essentially a sympathetic ganglion in which the postgang cells have lost their axons and secrete both <strong>norepinephrine</strong> and <strong>epinephrine</strong> directly into the bloodstream.</li>\n</ul>\n<h3 id=\"describe-synthesis-metabolism-storage-and-termination-of-action-of-those-neurotransmitters\">Describe synthesis, metabolism, storage, and termination of action of those neurotransmitters</h3>\n<hr>\n<ol>\n<li>Neurotransmitters are synthesized</li>\n<li>Stored in the nerve endings</li>\n<li>Released near the neurons, muscle cells, or gland cells</li>\n<li>They bind to various ion channels or G-protein-coupled receptors (GPCR)</li>\n<li>Initiate their characteristic actions. </li>\n<li>The neurotransmitters are then removed from the area by reuptake or metabolism. </li>\n</ol>\n<ul>\n<li>Each of these steps can be stimulated or inhibited, with predictable consequences.</li>\n</ul>\n<h3 id=\"list-respective-receptors-and-subtypes-describe-the-main-transduction-mechanisms-and-when-the-receptors-are-stimulated\">List respective receptors and subtypes. Describe the main transduction mechanisms and when the receptors are stimulated.</h3>\n<hr>\n<h3 id=\"nicotinic\">Nicotinic</h3>\n<ul>\n<li><strong>ACh from postgang acting on Nicotinic Receptors</strong>:  Causes a Na or K channel to open and depolarization. Nicotinic Receptors are ligand-gated ion channels. <ul>\n<li>Nn receptors are in autonomic ganglia. Blocked by hexamethonium.</li>\n<li>Nm receptors in neuromuscular junctions and blocked by curare.</li>\n</ul>\n</li>\n<li>Responses by post-gang include: Fast EPSP that generates AP’s and is produced by ACh on Nn receptors. Slow EPSP which modulates transmission through sympathetic gang and is produced by ACh on muscarinic receptor on post-gang neuron.<h3 id=\"muscarinic\">Muscarinic</h3>\n</li>\n<li><strong>ACh from postgang acting on muscarinic cholinergic receptors</strong>: Act on GPCR’s and have a activating or inhibitory effect depending on what class of receptor.</li>\n<li>Muscarinic receptors and are blocked by <strong>atropine</strong>. </li>\n<li><strong>Muscarinic</strong> receptors are GPCR and are divided into subtypes:<ul>\n<li>M1–M5; M2 and M3 in autonomic target organs. </li>\n<li>M2 receptors are found in the heart<ul>\n<li>Binding agonist opens K+ channels and inhibits adenylyl cyclase. </li>\n</ul>\n</li>\n<li>M3 receptors are located on smooth muscle and glands <ul>\n<li>Binding agonist leads to (IP3) &amp; (DAG) &gt;&gt; increase in Ca2+.</li>\n</ul>\n</li>\n</ul>\n</li>\n<li>Compounds with muscarinic actions include congeners of acetylcholine and drugs that inhibit acetylcholinesterase.<ul>\n<li>Cholinesterase Inhibitor Effects: <strong>Inhibits the breakdown of ACh, so increase the muscarinic effect</strong><ul>\n<li>Excessive activation of autonomic muscarinic receptors; these include miosis, salivation, sweating, bronchial constriction, vomiting, and diarrhea. </li>\n<li>CNS signs of toxicity include cognitive disturbances, convulsions, seizures, and even coma; these signs are often accompanied by nicotinic effects such as depolarizing neuromuscular blockade.</li>\n</ul>\n</li>\n<li>Muscarinc Cholinergic Receptor Antagonist: Atropine <strong>Blocks ACh from binding to muscarinic receptors, decreasing the effect</strong><h3 id=\"noradrenergic\">Noradrenergic</h3>\n<ul>\n<li>Norepinephrine spreads farther and has a more prolonged action than acetylcholine. </li>\n<li>Norepinephrine, epinephrine, and dopamine are all found in plasma. </li>\n</ul>\n</li>\n</ul>\n<ul>\n<li>The epinephrine and some of the dopamine come from the adrenal medulla</li>\n<li>But most of the norepinephrine diffuses into the bloodstream from sympathetic nerve endings.</li>\n</ul>\n</li>\n<li>Norepinephrine released from sympathetic post-gang binds to adrenoceptors: <ul>\n<li><strong>GPCR α1, α2, β1, β2, and β3.</strong></li>\n<li>Binding α1 → Gq → IP3+DAG = ↑↑↑↑ Ca2+. </li>\n<li>Binding α2 → Gi X adenylyl cyclase ↓↓↓↓ cAMP. </li>\n<li>Binding  β → Gs → adenylyl cyclase ↑↑↑↑ cAMP.</li>\n</ul>\n</li>\n<li>Horner syndrome is a result of dysfunctional sympathetic innervation.<ul>\n<li>Anhidrosis (reduced sweating), ptosis (drooping eyelid), and miosis (constricted pupil). Also enophthalmos (sunken eyeball) and vasodilation.</li>\n</ul>\n</li>\n</ul>\n<hr>\n<table>\n<thead>\n<tr>\n<th></th>\n<th>Ligands of Adrenoceptors</th>\n<th></th>\n<th></th>\n</tr>\n</thead>\n<tbody><tr>\n<td>Alpha1</td>\n<td>Vasoconstriction, ↑ TPR, BP, Myadriasis, Bladder closes.</td>\n<td>Norepi</td>\n<td>Epi</td>\n</tr>\n<tr>\n<td>Alpha2</td>\n<td>Presynaptic adrenergic nerve terminals. ↓ Norepi release, ACh release, Insulin release</td>\n<td>Norepi</td>\n<td>Epi</td>\n</tr>\n<tr>\n<td>Beta1</td>\n<td>Postsynaptic effector cells, Tachycardia, ↑ Lipolysis, myocardial contractility, renin release</td>\n<td>Norepi</td>\n<td>Epi</td>\n</tr>\n<tr>\n<td>Beta2</td>\n<td>Postsynaptic effector cells, Vasodilation, ↓ TPR, ↑ glucagon, ↓ relax uterine muscle muscle</td>\n<td></td>\n<td>Epi</td>\n</tr>\n<tr>\n<td>Beta3</td>\n<td>Postsynaptic effector cells, especially lipocytes; heart</td>\n<td>Norepi</td>\n<td></td>\n</tr>\n</tbody></table>\n<hr>\n<h3 id=\"associate-target-organs-and-physiological-action-when-receptors-are-stimulated-consider-the-affinities-when-descrbing-norephedrine-and-epinephrine\">Associate target organs and physiological action when receptors are stimulated. Consider the affinities, when descrbing norephedrine and epinephrine.</h3>\n<hr>\n<ul>\n<li>Adrenergic neurons transport precusor amino acid tyrosine to the nerve ending, convert it to dopa, and then synthesize a catecholamine (dopamine, norepi, epi)</li>\n<li>In most sympathetic postganglionic neurons, norepinephrine is the final product. </li>\n<li>In the adrenal medulla and certain areas of the brain, some norepinephrine is further converted to epinephrine. In dopaminergic neurons, synthesis terminates with dopamine.</li>\n<li>ACh by α-motor neurons only leads to contraction of skeletal muscles. </li>\n<li>ACh onto smooth muscle organs leads to contraction (eg, walls of the gastrointestinal tract) or relaxation (eg, sphincters in the gastrointestinal tract).</li>\n<li>The only way to relax a skeletal muscle is to stop discharging from motor neuron.</li>\n<li>For muscle innervated by ANS:<ul>\n<li>contraction can shift to relaxation by switching from parasympathetic to sympathetic.</li>\n<li>Dual innervation with antagonistic effects:<ul>\n<li>heart, airways, digestive tract, and urinary bladder</li>\n</ul>\n</li>\n<li>Antagonistic Version: <ul>\n<li><strong>sympathetic increases heart rate</strong></li>\n<li><strong>parasympathetic decreases heart rate</strong></li>\n</ul>\n</li>\n<li>Complementary Version:<ul>\n<li><strong>Parasympathetic causes release of watery saliva</strong></li>\n<li><strong>Sympathetic causes production of thick, viscous saliva.</strong></li>\n</ul>\n</li>\n<li>Synergistic Version:<ul>\n<li>Control of pupil diameter in the eye. </li>\n<li><strong>Sympathetic and parasympathetic are excitatory.</strong></li>\n<li><strong>Sympathetic</strong> contracts the radial (or dilator) muscle to cause <strong>mydriasis (widening of the pupil)</strong></li>\n<li><strong>Parasympathetic</strong> contracts the sphincter (or constrictor) muscle to cause <strong>miosis (narrowing of the pupil)</strong></li>\n</ul>\n</li>\n<li>Exclusivity:<ul>\n<li>Sympathetic: Adrenal gland, most blood vessels, the pilomotor muscles, sweat glands.</li>\n<li>Parasympathetic: lacrimal muscle, ciliary muscle, and nasopharyngeal gland.</li>\n</ul>\n</li>\n<li>Fight or Flight: Sympathetic<ul>\n<li>Dilates the pupils (letting more light into the eyes)</li>\n<li>Accelerates the heartbeat and raises the blood pressure (providing better perfusion of the vital organs and muscles)</li>\n<li>Constricts the blood vessels of the skin (which limits bleeding from wounds). </li>\n<li>Noradrenergic discharge also leads to elevated plasma glucose and free fatty acid levels</li>\n</ul>\n</li>\n<li>Rest and Digest: Parasympathetic<ul>\n<li>Favors digestion and absorption of food. </li>\n<li>Increase the activity of the intestinal musculature</li>\n<li>Increase gastric secretion</li>\n<li>Relax the pyloric sphincter</li>\n</ul>\n</li>\n</ul>\n</li>\n</ul>\n<hr>\n<h3 id=\"list-effects-triggered-by-ach-and-catecholamines-ne-da-acting-on-the-cns\">List effects triggered by ACh and catecholamines (NE, DA), acting on the CNS.</h3>\n<h3 id=\"end-of-chapter-notes\">End of Chapter Notes:</h3>\n<ul>\n<li><p>Preganglionic sympathetic neurons are located in the spinal thoracolumbar IML and project to postganglionic neurons in the paravertebral or prevertebral ganglia or the adrenal medulla. Preganglionic parasympathetic neurons are located in motor nuclei of cranial nerves III, VII, IX, and X and the sacral IML and project to ganglia located in or near the effector target. The targets of the ANS include smooth muscle, cardiac muscle and pacemaker cells, exocrine and endocrine glands, adipose tissue, liver cells, and lymphatic tissue.</p>\n</li>\n<li><p>Acetylcholine is released at nerve terminals of all preganglionic neurons, postganglionic parasympathetic neurons, and a few postganglionic sympathetic neurons (sweat glands and sympathetic vasodilator fibers). The remaining sympathetic postganglionic neurons release norepinephrine.</p>\n</li>\n<li><p>Ganglionic transmission is mediated by activation of nicotinic receptors. Postganglionic cholinergic transmission is mediated by activation of muscarinic receptors. Postganglionic adrenergic transmission is mediated by activation of α1-, β-, or β2-adrenoceptors, depending on the target organ.</p>\n</li>\n<li><p>Many commonly used drugs exert their therapeutic actions by serving as agonists (eg, bethanecol, phenylephrine, albuterol) or antagonists (eg, atropine, phenoxybenzamine, atenolol) at autonomic synapses, by blocking neurotransmitter synthesis (eg, metyrosine), or by blocking neurotransmitter release (eg, tricyclic antidepressants).</p>\n</li>\n<li><p>The ANS works in concert with the endocrine system to maintain homeostasis or a stable internal environment despite challenges imposed by shifts in things such as air temperature, oxygen and carbon dioxide levels, physical activity, exposure to toxins, disease, drug therapies, fever, and diet.</p>\n</li>\n<li><p>Sympathetic activity prepares the individual to cope with an emergency by accelerating the heartbeat, raising blood pressure (perfusion of the vital organs), and constricting the blood vessels of the skin (limits bleeding from wounds). Parasympathetic activity is concerned with the vegetative aspects of day-to-day living and favors digestion and absorption of food by increasing the activity of the intestinal musculature, increasing gastric secretion, and relaxing the pyloric sphincter.</p>\n</li>\n<li><p>At many organs that receive dual innervation (eg, heart, airways, digestive tract, and urinary bladder), the two divisions of the ANS act as physiological antagonists. In other cases, the two divisions of the ANS can act in a synergistic manner in the control of some functions (eg, control of pupil diameter). Some organs are innervated by only the sympathetic (eg, blood vessels) or only parasympathetic (eg, ciliary muscle) nervous system.</p>\n</li>\n<li><p>Direct projections to sympathetic preganglionic neurons in the IML originate in the hypothalamic paraventricular nucleus, pontine catecholaminergic A5 cell group, rostral ventrolateral medulla, and medullary raphe nuclei.</p>\n</li>\n<li><p>The enteric nervous system is located within the wall of the digestive tract and is composed of the myenteric plexus (control of digestive tract motility) and the submucosal plexus (regulates gastrointestinal blood flow and epithelial cell function).</p>\n</li>\n</ul>\n<h3 id=\"adrenergic-junctions\">Adrenergic Junctions</h3>\n<ul>\n<li>Schematic diagram of a generalized noradrenergic junction (not to scale). Tyrosine is transported into the noradrenergic nerve ending or varicosity by a sodium-dependent carrier (A). Tyrosine is converted to dopamine (see Figure 6–5 for details), and transported into the vesicle by the vesicular monoamine transporter (VMAT), which can be blocked by reserpine and tetrabenazine. The same carrier transports norepinephrine (NE) and several related amines into these vesicles. Dopamine is converted to NE in the vesicle by dopamine-β-hydroxylase. Physiologic release of transmitter occurs when an action potential opens voltage-sensitive calcium channels and increases intracellular calcium. Fusion of vesicles with the surface membrane results in expulsion of norepinephrine, cotransmitters, and dopamine-β-hydroxylase. Release can be blocked by drugs such as guanethidine and bretylium. After release, norepinephrine diffuses out of the cleft or is transported into the cytoplasm of the terminal by the norepinephrine transporter (NET), which can be blocked by cocaine and certain antidepressants, or into postjunctional or perijunctional cells. Regulatory receptors are present on the presynaptic terminal. SNAPs, synaptosome-associated proteins; VAMPs, vesicle-associated membrane proteins.\n<figure class=\"post__image\"><img loading=\"lazy\" src=\"adr_rec.png\" data-is-external-image=\"true\"  alt=\"Adrenergic_Receptor\" /></figure></li>\n</ul>\n<table>\n<thead>\n<tr>\n<th>Effector Organs</th>\n<th>Parasympathetic Nervous System</th>\n<th>Sympathetic Nervous System</th>\n</tr>\n</thead>\n<tbody><tr>\n<td>Receptor Type</td>\n<td>Response</td>\n<td></td>\n</tr>\n<tr>\n<td>Eyes</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Radial muscle of iris</td>\n<td>—</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Sphincter muscle of iris</td>\n<td>Contraction (miosis)</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Ciliary muscle</td>\n<td>Contraction for near vision</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Heart</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>SA node</td>\n<td>Decreased heart rate</td>\n<td>β1</td>\n</tr>\n<tr>\n<td>Atria and ventricle</td>\n<td>Decreased atrial contractility</td>\n<td>β1, β2</td>\n</tr>\n<tr>\n<td>AV node and Purkinje fibers</td>\n<td>Decreased conduction velocity</td>\n<td>β1</td>\n</tr>\n<tr>\n<td>Arterioles</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Skin, splanchnic vessels</td>\n<td>—</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Skeletal muscle</td>\n<td>—</td>\n<td>α1/ β2, M</td>\n</tr>\n<tr>\n<td>Systemic veins</td>\n<td>—</td>\n<td>α1, α2/ β2</td>\n</tr>\n<tr>\n<td>Bronchial smooth muscle</td>\n<td>Contraction</td>\n<td>β2</td>\n</tr>\n<tr>\n<td>Stomach and Intestine</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Motility and tone</td>\n<td>Increased</td>\n<td>α1, α2, β2</td>\n</tr>\n<tr>\n<td>Sphincters</td>\n<td>Relaxation</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Secretion</td>\n<td>Stimulation</td>\n<td>—</td>\n</tr>\n<tr>\n<td>Gallbladder</td>\n<td>Contraction</td>\n<td>β2</td>\n</tr>\n<tr>\n<td>Urinary bladder</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Detrusor</td>\n<td>Contraction</td>\n<td>β2</td>\n</tr>\n<tr>\n<td>Sphincter</td>\n<td>Relaxation</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Uterus (pregnant)</td>\n<td>—</td>\n<td>α1/ β2</td>\n</tr>\n<tr>\n<td>Male sex organs</td>\n<td>Erection</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Skin</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Pilomotor muscles</td>\n<td>—</td>\n<td>α1</td>\n</tr>\n<tr>\n<td>Sweat glands</td>\n<td>—</td>\n<td>M</td>\n</tr>\n<tr>\n<td>Liver</td>\n<td>—</td>\n<td>α1, β2</td>\n</tr>\n<tr>\n<td>Pancreas</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Acini</td>\n<td>Increased secretion</td>\n<td>α</td>\n</tr>\n<tr>\n<td>Islet cells</td>\n<td>—</td>\n<td>α2/β2</td>\n</tr>\n<tr>\n<td>Salivary glands</td>\n<td>Profuse, watery secretion</td>\n<td>α1/β</td>\n</tr>\n<tr>\n<td>Lacrimal glands</td>\n<td>Secretion</td>\n<td></td>\n</tr>\n<tr>\n<td>Adipose tissue</td>\n<td>—</td>\n<td>β3</td>\n</tr>\n</tbody></table>\n<p>.  \n.<br>.  \n.  </p>\n<table>\n<thead>\n<tr>\n<th>Receptor Name</th>\n<th>Typical Locations</th>\n<th>Result of Ligand Binding</th>\n</tr>\n</thead>\n<tbody><tr>\n<td>Cholinoceptors</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Muscarinic M1</td>\n<td>CNS neurons, sympathetic postganglionic neurons, some presynaptic sites</td>\n<td>Formation of IP3 and DAG, increased intracellular calcium</td>\n</tr>\n<tr>\n<td>Muscarinic M2</td>\n<td>Myocardium, smooth muscle, some presynaptic sites; CNS neurons</td>\n<td>Opening of potassium channels, inhibition of adenylyl cyclase</td>\n</tr>\n<tr>\n<td>Muscarinic M3</td>\n<td>Exocrine glands, vessels (smooth muscle and endothelium); CNS neurons</td>\n<td>Like M1 receptor-ligand binding</td>\n</tr>\n<tr>\n<td>Muscarinic M4</td>\n<td>CNS neurons; possibly vagal nerve endings</td>\n<td>Like M2 receptor-ligand binding</td>\n</tr>\n<tr>\n<td>Muscarinic M5</td>\n<td>Vascular endothelium, especially cerebral vessels; CNS neurons</td>\n<td>Like M1 receptor-ligand binding</td>\n</tr>\n<tr>\n<td>Nicotinic NN</td>\n<td>Postganglionic neurons, some presynaptic cholinergic terminals; pentameric receptors typically contain α- and β-type subunits only</td>\n<td>Opening of Na<sup>+</sup>, K<sup>+</sup> channels, depolarization</td>\n</tr>\n<tr>\n<td>Nicotinic NM</td>\n<td>Skeletal muscle neuromuscular end plates; receptors typically contain two α1- and β1-type subunits in addition to γ and δ subunits</td>\n<td>Opening of Na<sup>+</sup>, K<sup>+</sup> channels, depolarization</td>\n</tr>\n<tr>\n<td>Adrenoceptors</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>Alpha1</td>\n<td>Postsynaptic effector cells, especially smooth muscle</td>\n<td>Formation of IP3 and DAG, increased intracellular calcium</td>\n</tr>\n<tr>\n<td>Alpha2</td>\n<td>Presynaptic adrenergic nerve terminals, platelets, lipocytes, smooth muscle</td>\n<td>Inhibition of adenylyl cyclase, decreased cAMP</td>\n</tr>\n<tr>\n<td>Beta1</td>\n<td>Postsynaptic effector cells, especially heart, lipocytes, brain; presynaptic adrenergic and cholinergic nerve terminals, juxtaglomerular apparatus of renal tubules, ciliary body epithelium</td>\n<td>Stimulation of adenylyl cyclase, increased cAMP</td>\n</tr>\n<tr>\n<td>Beta2</td>\n<td>Postsynaptic effector cells, especially smooth muscle and cardiac muscle</td>\n<td>Stimulation of adenylyl cyclase and increased cAMP. Activates cardiac Gi under some conditions.</td>\n</tr>\n<tr>\n<td>Beta3</td>\n<td>Postsynaptic effector cells, especially lipocytes; heart</td>\n<td>Stimulation of adenylyl cyclase and increased cAMP<sup>1</sup></td>\n</tr>\n<tr>\n<td>Dopamine receptors</td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>D1 (DA1), D5</td>\n<td>Brain; effector tissues, especially smooth muscle of the renal vascular bed</td>\n<td>Stimulation of adenylyl cyclase and increased cAMP</td>\n</tr>\n<tr>\n<td>D2 (DA2)</td>\n<td>Brain; effector tissues, especially smooth muscle; presynaptic nerve terminals</td>\n<td>Inhibition of adenylyl cyclase; increased potassium conductance</td>\n</tr>\n<tr>\n<td>D3</td>\n<td>Brain</td>\n<td>Inhibition of adenylyl cyclase</td>\n</tr>\n<tr>\n<td>D4</td>\n<td>Brain, cardiovascular system</td>\n<td>Inhibition of adenylyl cyclase</td>\n</tr>\n</tbody></table>\n<p>.  \n.<br>.  \n.  </p>\n<table>\n<thead>\n<tr>\n<th>Process Affected</th>\n<th>Drug Example</th>\n<th>Site</th>\n<th>Action</th>\n</tr>\n</thead>\n<tbody><tr>\n<td>Action potential propagation</td>\n<td>Local anesthetics, tetrodotoxin, saxitoxin</td>\n<td>Nerve axons</td>\n<td>Block voltage-gated sodium channels; block conduction</td>\n</tr>\n<tr>\n<td>Transmitter synthesis</td>\n<td>Hemicholiniums</td>\n<td>Cholinergic nerve terminals: membrane</td>\n<td>Block uptake of choline and slow ACh synthesis</td>\n</tr>\n<tr>\n<td></td>\n<td>α-Methyltyrosine (metyrosine)</td>\n<td>Adrenergic nerve terminals and adrenal medulla: cytoplasm</td>\n<td>Inhibits tyrosine hydroxylase and blocks synthesis of catecholamines</td>\n</tr>\n<tr>\n<td>Transmitter storage</td>\n<td>Vesamicol</td>\n<td>Cholinergic terminals: VAT on vesicles</td>\n<td>Prevents storage, depletes</td>\n</tr>\n<tr>\n<td></td>\n<td>Reserpine, tetrabenazine</td>\n<td>Adrenergic terminals: VMAT on vesicles</td>\n<td>Prevents storage, depletes</td>\n</tr>\n<tr>\n<td>Transmitter release</td>\n<td>Many</td>\n<td>Nerve terminal membrane receptors</td>\n<td>Modulate release</td>\n</tr>\n<tr>\n<td></td>\n<td>ω-Conotoxin GVIA</td>\n<td>Nerve terminal calcium channels</td>\n<td>Reduces transmitter release</td>\n</tr>\n<tr>\n<td></td>\n<td>Domoic acid</td>\n<td>Nerve terminal kainate receptors (primarily CNS)</td>\n<td>Modulates transmitter release by altering calcium influx/release</td>\n</tr>\n<tr>\n<td></td>\n<td>Botulinum toxin</td>\n<td>Cholinergic vesicles</td>\n<td>Prevents ACh release</td>\n</tr>\n<tr>\n<td></td>\n<td>α-Latrotoxin</td>\n<td>Cholinergic and adrenergic vesicles</td>\n<td>Causes explosive transmitter release</td>\n</tr>\n<tr>\n<td></td>\n<td>Tyramine, amphetamine</td>\n<td>Adrenergic nerve terminals</td>\n<td>Promote transmitter release</td>\n</tr>\n<tr>\n<td>Transmitter reuptake after release</td>\n<td>Cocaine, tricyclic antidepressants, SNRI antidepressants</td>\n<td>Adrenergic nerve terminals, NET</td>\n<td>Inhibit uptake; increase transmitter effect on postsynaptic receptors</td>\n</tr>\n<tr>\n<td>Receptor activation or blockade</td>\n<td>Norepinephrine</td>\n<td>Receptors at adrenergic junctions</td>\n<td>Binds and activates a receptors; causes contraction</td>\n</tr>\n<tr>\n<td></td>\n<td>Phentolamine</td>\n<td>Receptors at adrenergic junctions</td>\n<td>Binds a receptors; prevents activation</td>\n</tr>\n<tr>\n<td></td>\n<td>Isoproterenol</td>\n<td>Receptors at adrenergic junctions</td>\n<td>Binds β receptors; activates adenylyl cyclase</td>\n</tr>\n<tr>\n<td></td>\n<td>Propranolol</td>\n<td>Receptors at adrenergic junctions</td>\n<td>Binds β receptors; prevents activation</td>\n</tr>\n<tr>\n<td></td>\n<td>Nicotine</td>\n<td>Receptors at nicotinic cholinergic junctions (autonomic ganglia, neuromuscular end plates)</td>\n<td>Binds nicotinic receptors; opens ion channel in postsynaptic membrane</td>\n</tr>\n<tr>\n<td></td>\n<td>Tubocurarine</td>\n<td>Neuromuscular end plates</td>\n<td>Prevents activation of nicotinic receptors</td>\n</tr>\n<tr>\n<td></td>\n<td>Bethanechol</td>\n<td>Receptors, parasympathetic effector cells (smooth muscle, glands)</td>\n<td>Binds and activates muscarinic receptors</td>\n</tr>\n<tr>\n<td></td>\n<td>Atropine</td>\n<td>Receptors, parasympathetic effector cells</td>\n<td>Binds muscarinic receptors; prevents activation</td>\n</tr>\n<tr>\n<td>Enzymatic inactivation of transmitter</td>\n<td>Neostigmine</td>\n<td>Cholinergic synapses (acetylcholinesterase)</td>\n<td>Inhibits enzyme; prolongs and intensifies transmitter action after release</td>\n</tr>\n<tr>\n<td></td>\n<td>Tranylcypromine</td>\n<td>Adrenergic nerve terminals (monoamine oxidase)</td>\n<td>Inhibits enzyme; increases stored transmitter pool</td>\n</tr>\n</tbody></table>\n",
            "author": {
                "name": "William Slattery"
            },
            "tags": [
            ],
            "date_published": "2020-11-30T11:58:15-05:00",
            "date_modified": "2020-12-02T23:05:24-05:00"
        }
    ]
}
